Fergus Shanahan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7404207/publications.pdf

Version: 2024-02-01

731 papers

54,995 citations

113
h-index

213 g-index

1005 all docs

1005 docs citations

1005 times ranked 45408 citing authors

#	Article	IF	CITATIONS
1	Gut microbiota composition correlates with diet and health in the elderly. Nature, 2012, 488, 178-184.	27.8	2,618
2	The gut flora as a forgotten organ. EMBO Reports, 2006, 7, 688-693.	4.5	2,226
3	The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Molecular Psychiatry, 2013, 18, 666-673.	7.9	1,445
4	Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4586-4591.	7.1	1,418
5	Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology, 2005, 128, 541-551.	1.3	1,276
6	Exercise and associated dietary extremes impact on gut microbial diversity. Gut, 2014, 63, 1913-1920.	12.1	987
7	The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand Journal of Experimental Medicine, 1996, 184, 1075-1082.	8.5	840
8	Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut, 2010, 59, 1635-1642.	12.1	808
9	Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome. American Journal of Gastroenterology, 2006, 101, 1581-1590.	0.4	739
10	Enterotypes in the landscape of gut microbial community composition. Nature Microbiology, 2018, 3, 8-16.	13.3	717
11	Microbiota is essential for social development in the mouse. Molecular Psychiatry, 2014, 19, 146-148.	7.9	708
12	In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. American Journal of Clinical Nutrition, 2001, 73, 386s-392s.	4.7	667
13	The role of substance P in inflammatory disease. Journal of Cellular Physiology, 2004, 201, 167-180.	4.1	658
14	Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut, 2017, 66, 633-643.	12.1	623
15	Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?. Lancet, The, 1994, 343, 71-74.	13.7	587
16	Hypothalamic-Pituitary-Gut Axis Dysregulation in Irritable Bowel Syndrome: Plasma Cytokines as a Potential Biomarker?. Gastroenterology, 2006, 130, 304-311.	1.3	544
17	Rapid and Noninvasive Metabonomic Characterization of Inflammatory Bowel Disease. Journal of Proteome Research, 2007, 6, 546-551.	3.7	539
18	A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. Journal of Allergy and Clinical Immunology, 1990, 86, 202-210.	2.9	505

#	Article	IF	Citations
19	Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 7421-7426.	7.1	471
20	Crohn's disease. Lancet, The, 2002, 359, 62-69.	13.7	467
21	Regulation of prefrontal cortex myelination by the microbiota. Translational Psychiatry, 2016, 6, e774-e774.	4.8	459
22	Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2108-2113.	7.1	450
23	The oral microbiota in colorectal cancer is distinctive and predictive. Gut, 2018, 67, 1454-1463.	12.1	425
24	Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut, 2003, 52, 975-980.	12.1	399
25	The gut microbiota and its relationship to diet and obesity. Gut Microbes, 2012, 3, 186-202.	9.8	382
26	Adult Hippocampal Neurogenesis Is Regulated by the Microbiome. Biological Psychiatry, 2015, 78, e7-e9.	1.3	363
27	<i><i>>i>Bifidobacterium infantis</i>>/i>35624 modulates host inflammatory processes beyond the gut. Gut Microbes, 2013, 4, 325-339.</i>	9.8	342
28	The microbiome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level. Gut, 2018, 67, gutjnl-2016-313627.	12.1	333
29	Neutrophil Cytoplasmic Antibodies: A Link Between Primary Sclerosing Cholangitis and Ulcerative Colitis. Gastroenterology, 1991, 100, 1385-1391.	1.3	332
30	Functional genome analysis of $\langle i \rangle$ Bifidobacterium breve $\langle i \rangle$ UCC2003 reveals type IVb tight adherence (Tad) pili as an essential and conserved host-colonization factor. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11217-11222.	7.1	328
31	Mast cell heterogeneity: effects of neuroenteric peptides on histamine release. Journal of Immunology, 1985, 135, 1331-7.	0.8	324
32	World Gastroenterology Organisation Global Guidelines. Journal of Clinical Gastroenterology, 2012, 46, 468-481.	2.2	321
33	Title is missing!. Antonie Van Leeuwenhoek, 1999, 76, 279-292.	1.7	320
34	Establishing or Exaggerating Causality for the Gut Microbiome: Lessons from Human Microbiota-Associated Rodents. Cell, 2020, 180, 221-232.	28.9	318
35	Inflammatory bowel disease: Immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology, 2001, 120, 622-635.	1.3	315
36	Commensal-Induced Regulatory T Cells Mediate Protection against Pathogen-Stimulated NF-κB Activation. PLoS Pathogens, 2008, 4, e1000112.	4.7	315

#	Article	IF	CITATIONS
37	Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews Gut, 1993, 34, 517-524.	12.1	314
38	Effect of broad- and narrow-spectrum antimicrobials on <i>Clostridium difficile</i> and microbial diversity in a model of the distal colon. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4639-4644.	7.1	313
39	The stress response and the hypothalamic-pituitary-adrenal axis: from molecule to melancholia. QJM - Monthly Journal of the Association of Physicians, 2000, 93, 323-333.	0.5	307
40	Crohn's disease: factors associated with exposure to high levels of diagnostic radiation. Gut, 2008, 57, 1524-1529.	12.1	307
41	Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Gastroenterology, 1991, 100, 1590-1596.	1.3	292
42	Phylogenetic Analysis of Dysbiosis in Ulcerative Colitis During Remission. Inflammatory Bowel Diseases, 2013, 19, 481-488.	1.9	285
43	BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Research, 2000, 60, 6171-7.	0.9	283
44	Culture-Independent Analyses of Temporal Variation of the Dominant Fecal Microbiota and Targeted Bacterial Subgroups in Crohn's Disease. Journal of Clinical Microbiology, 2006, 44, 3980-3988.	3.9	277
45	Exploring the Diversity of the Bifidobacterial Population in the Human Intestinal Tract. Applied and Environmental Microbiology, 2009, 75, 1534-1545.	3.1	270
46	Distinct associations of HLA Class II genes with inflammatory bowel disease. Gastroenterology, 1993, 104, 741-748.	1.3	263
47	Adult microbiotaâ€deficient mice have distinct dendritic morphological changes: differential effects in the amygdala and hippocampus. European Journal of Neuroscience, 2016, 44, 2654-2666.	2.6	263
48	Categorization of the gut microbiota: enterotypes or gradients?. Nature Reviews Microbiology, 2012, 10, 591-592.	28.6	260
49	Probiotic impact on microbial flora, inflammation and tumour development in ILâ€10 knockout mice. Alimentary Pharmacology and Therapeutics, 2001, 15, 1219-1225.	3.7	255
50	Functional modulation of human intestinal epithelial cell responses by <i>Bifidobacterium infantis </i> and <i>Lactobacillus salivarius</i> lmmunology, 2006, 118, 202-215.	4.4	248
51	Enterococcus faecalis Metalloprotease Compromises Epithelial Barrier and Contributes to Intestinal Inflammation. Gastroenterology, 2011, 141, 959-971.	1.3	246
52	<i>Bifidobacterium infantis</i> 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut, 2012, 61, 354-366.	12.1	242
53	Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut, 2008, 57, 1185-1191.	12.1	239
54	Movers and shakers. Gut Microbes, 2013, 4, 4-16.	9.8	236

#	Article	IF	CITATIONS
55	Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. Gut, 2013, 62, 220-226.	12.1	235
56	The host–microbe interface within the gut. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2002, 16, 915-931.	2.4	231
57	A Molecular Analysis of Fecal and Mucosal Bacterial Communities in Irritable Bowel Syndrome. Digestive Diseases and Sciences, 2010, 55, 392-397.	2.3	228
58	Spatial variation of the colonic microbiota in patients with ulcerative colitis and control volunteers. Gut, 2015, 64, 1553-1561.	12.1	226
59	Inclusion of the Mesentery in Ileocolic Resection for Crohn's Disease is Associated With Reduced Surgical Recurrence. Journal of Crohn's and Colitis, 2018, 12, 1139-1150.	1.3	223
60	Disturbance of the gut microbiota in early-life selectively affects visceral pain in adulthood without impacting cognitive or anxiety-related behaviors in male rats. Neuroscience, 2014, 277, 885-901.	2.3	222
61	The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. Journal of Immunology, 1998, 160, 5669-75.	0.8	219
62	The Fas counterattack: cancer as a site of immune privilege. Trends in Immunology, 1999, 20, 46-52.	7. 5	218
63	Bacteriophages i-MR299-2 and i-NH-4 Can Eliminate Pseudomonas aeruginosa in the Murine Lung and on Cystic Fibrosis Lung Airway Cells. MBio, 2012, 3, e00029-12.	4.1	218
64	Multireplicon genome architecture of Lactobacillus salivarius. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6718-6723.	7.1	216
65	Cultureâ€independent analysis of the gut microbiota in colorectal cancer and polyposis. Environmental Microbiology, 2008, 10, 789-798.	3.8	216
66	Microbes & amp; neurodevelopment – Absence of microbiota during early life increases activity-related transcriptional pathways in the amygdala. Brain, Behavior, and Immunity, 2015, 50, 209-220.	4.1	210
67	Time to abandon the hygiene hypothesis: new perspectives on allergic disease, the human microbiome, infectious disease prevention and the role of targeted hygiene. Perspectives in Public Health, 2016, 136, 213-224.	1.6	206
68	Patchiness of mucosal inflammation in treated ulcerative colitis: A prospective study. Gastrointestinal Endoscopy, 1995, 42, 232-237.	1.0	204
69	Irritable Bowel Syndrome–Type Symptoms in Patients With Inflammatory Bowel Disease: A Real Association or Reflection of Occult Inflammation?. American Journal of Gastroenterology, 2010, 105, 1789-1794.	0.4	204
70	Insulin-dependent diabetes mellitus and coeliac disease. Lancet, The, 1997, 349, 1096-1097.	13.7	201
71	Oral Mesalamine (Asacol) for Mildly to Moderately Active Ulcerative Colitis. Annals of Internal Medicine, 1991, 115, 350-355.	3.9	196
72	The microbiota in inflammatory bowel disease. Journal of Gastroenterology, 2015, 50, 495-507.	5.1	196

#	Article	IF	CITATIONS
73	Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor ν Leiden. QJM - Monthly Journal of the Association of Physicians, 1997, 90, 183-188.	0.5	190
74	Bacterial strainâ€specific induction of Foxp3 ⁺ T regulatory cells is protective in murine allergy models. Clinical and Experimental Allergy, 2010, 40, 811-819.	2.9	189
75	Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. Journal of Bone and Mineral Research, 1995, 10, 250-256.	2.8	187
76	Clostridium difficile Carriage in Elderly Subjects and Associated Changes in the Intestinal Microbiota. Journal of Clinical Microbiology, 2012, 50, 867-875.	3.9	184
77	Neutrophil autoantibodies in ulcerative colitis: Familial aggregation and genetic heterogeneity. Gastroenterology, 1992, 103, 456-461.	1.3	183
78	Differential Expression of Toll-Like Receptors in Patients With Irritable Bowel Syndrome. American Journal of Gastroenterology, 2011, 106, 329-336.	0.4	178
79	The Vexed Relationship Between Clostridium Difficile and Inflammatory Bowel Disease: An Assessment of Carriage in an Outpatient Setting Among Patients in Remission. American Journal of Gastroenterology, 2009, 104, 1162-1169.	0.4	177
80	The Healthy Microbiomeâ€"What Is the Definition of a Healthy Gut Microbiome?. Gastroenterology, 2021, 160, 483-494.	1.3	174
81	Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut, 2004, 53, 694-700.	12.1	170
82	Micrometastases in esophagogastric cancer: High detection rate in resected rib segments. Gastroenterology, 1999, 116, 543-548.	1.3	169
83	Antimicrobial activity of lacticin 3147 against clinical Clostridium difficile strains. Journal of Medical Microbiology, 2007, 56, 940-946.	1.8	167
84	Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease. Nature Communications, 2020, 11, 1512.	12.8	167
85	Small Intestinal Bacterial Overgrowth in Nonalcoholic Steatohepatitis: Association with Toll-Like Receptor 4 Expression and Plasma Levels of Interleukin 8. Digestive Diseases and Sciences, 2011, 56, 1524-1534.	2.3	165
86	Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues. American Journal of Clinical Nutrition, 2009, 89, 1393-1401.	4.7	162
87	The gut microbiome as a modulator of healthy ageing. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 565-584.	17.8	162
88	Bacterial DNA within Granulomas of Patients with Crohn's Disease-Detection by Laser Capture Microdissection and PCR. American Journal of Gastroenterology, 2004, 99, 1539-1543.	0.4	161
89	Human methanogen diversity and incidence in healthy and diseased colonic groups using mcrA gene analysis. BMC Microbiology, 2008, 8, 79.	3.3	158
90	Immune privilege or inflammation? Insights into the Fas ligand enigma. Nature Medicine, 2001, 7, 271-274.	30.7	152

#	Article	IF	Citations
91	Mucosal cytokine imbalance in irritable bowel syndrome. Scandinavian Journal of Gastroenterology, 2008, 43, 1467-1476.	1.5	150
92	Manipulation of the Microbiota for Treatment of IBS and IBDâ€"Challenges and Controversies. Gastroenterology, 2014, 146, 1554-1563.	1.3	149
93	A Prospective Metagenomic and Metabolomic Analysis of the Impact of Exercise and/or Whey Protein Supplementation on the Gut Microbiome of Sedentary Adults. MSystems, 2018, 3, .	3.8	148
94	Probiotics and Inflammatory Bowel Disease: Is There a Scientific Rationale?. Inflammatory Bowel Diseases, 2000, 6, 107-115.	1.9	147
95	Plasma Cytokine Profiles in Females With Irritable Bowel Syndrome and Extra-Intestinal Co-Morbidity. American Journal of Gastroenterology, 2010, 105, 2235-2243.	0.4	146
96	The microbiome regulates amygdala-dependent fear recall. Molecular Psychiatry, 2018, 23, 1134-1144.	7.9	146
97	Triggered human mucosal T cells release tumour necrosis factor-alpha and interferon-gamma which kill human colonic epithelial cells. Clinical and Experimental Immunology, 2008, 83, 79-84.	2.6	145
98	A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Alimentary Pharmacology and Therapeutics, 1996, 10, 777-786.	3.7	142
99	Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 725-740.	2.4	141
100	Probiotic Effects on Inflammatory Bowel Disease1,. Journal of Nutrition, 2007, 137, 819S-824S.	2.9	137
101	Probiotics in obese pregnancy do not reduce maternal fasting glucose: a double-blind, placebo-controlled, randomized trial (Probiotics in Pregnancy Study). American Journal of Clinical Nutrition, 2014, 99, 1432-1439.	4.7	135
102	Microbial regulation of microRNA expression in the amygdala and prefrontal cortex. Microbiome, 2017, 5, 102.	11.1	133
103	Targeting the Microbiota to Address Diet-Induced Obesity: A Time Dependent Challenge. PLoS ONE, 2013, 8, e65790.	2.5	132
104	Celiac disease and irritable bowel-type symptoms. American Journal of Gastroenterology, 2002, 97, 1463-1467.	0.4	129
105	Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. American Journal of Human Genetics, 1996, 59, 676-83.	6.2	129
106	Microbiomic analysis of the bifidobacterial population in the human distal gut. ISME Journal, 2009, 3, 745-751.	9.8	128
107	Exercise and the microbiota. Gut Microbes, 2015, 6, 131-136.	9.8	127
108	Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study. Gut, 2021, 70, 499-510.	12.1	127

#	Article	IF	Citations
109	Feeding the microbiota: transducer of nutrient signals for the host. Gut, 2017, 66, 1709-1717.	12.1	124
110	Quantification of the placebo response in ulcerative colitis. Gastroenterology, 1997, 112, 1854-1858.	1.3	123
111	Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut, 1999, 44, 156-162.	12.1	123
112	Enhanced Cholinergic-Mediated Increase in the Pro-Inflammatory Cytokine IL-6 in Irritable Bowel Syndrome: Role of Muscarinic Receptors. American Journal of Gastroenterology, 2008, 103, 2570-2576.	0.4	122
113	Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption. Gastroenterology, 2020, 158, 1016-1028.e8.	1.3	122
114	Neurokinin-1 receptor expression in inflammatory bowel disease: molecular quantitation and localisation. Gut, 2000, 47, 387-396.	12.1	121
115	An International Survey of The Use and Attitudes Regarding Alternative Medicine by Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 1999, 94, 1298-1303.	0.4	117
116	Sulfate-Reducing Bacteria Colonize Pouches Formed for Ulcerative Colitis but Not for Familial Adenomatous Polyposis. Diseases of the Colon and Rectum, 2002, 45, 384-388.	1.3	117
117	Microbiota regulates visceral pain in the mouse. ELife, 2017, 6, .	6.0	117
118	Gut Microbiota: Mining for Therapeutic Potential. Clinical Gastroenterology and Hepatology, 2007, 5, 274-284.	4.4	116
119	Culture-independent analysis of desulfovibrios in the human distal colon of healthy, colorectal cancer and polypectomized individuals. FEMS Microbiology Ecology, 2009, 69, 213-221.	2.7	116
120	The normal intestinal microbiota. Current Opinion in Infectious Diseases, 2007, 20, 508-513.	3.1	114
121	Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. American Journal of Gastroenterology, 1995, 90, 2106-14.	0.4	113
122	Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer., 1998, 186, 240-246.		112
123	PCR detection of Mycobacterium paratuberculosis in Crohn's disease granulomas isolated by laser capture microdissection. Gut, 2002, 51, 665-670.	12.1	111
124	A Randomized Controlled Study of Mesalamine After Acute Diverticulitis. Journal of Clinical Gastroenterology, 2013, 47, 621-629.	2.2	110
125	Contrasting effects of Bifidobacterium breve NCIMB 702258 and Bifidobacterium breve DPC 6330 on the composition of murine brain fatty acids and gut microbiota. American Journal of Clinical Nutrition, 2012, 95, 1278-1287.	4.7	109
126	Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferonâ€gamma, severity of symptoms and psychiatric coâ€morbidity. Neurogastroenterology and Motility, 2008, 20, 1291-1297.	3.0	108

#	Article	IF	Citations
127	IL-36α expression is elevated in ulcerative colitis and promotes colonic inflammation. Mucosal Immunology, 2016, 9, 1193-1204.	6.0	106
128	Gut microbiota alterations associated with reduced bone mineral density in older adults. Rheumatology, 2019, 58, 2295-2304.	1.9	106
129	Portrait of an immunoregulatory bifidobacterium. Gut Microbes, 2012, 3, 261-266.	9.8	104
130	The altered gut microbiota in adults with cystic fibrosis. BMC Microbiology, 2017, 17, 58.	3.3	104
131	Probiotics in inflammatory bowel diseaseâ€"therapeutic rationale and role. Advanced Drug Delivery Reviews, 2004, 56, 809-818.	13.7	103
132	Acromegaly and Colorectal Cancer: A Comprehensive Review of Epidemiology, Biological Mechanisms, and Clinical Implications. Hormone and Metabolic Research, 2003, 35, 712-725.	1.5	101
133	Micrometastases: marker of metastatic potential or evidence of residual disease?. Gut, 1997, 40, 512-515.	12.1	100
134	Identification of TLR10 as a Key Mediator of the Inflammatory Response to <i>Listeria monocytogenes</i> in Intestinal Epithelial Cells and Macrophages. Journal of Immunology, 2013, 191, 6084-6092.	0.8	99
135	Bacterial bile salt hydrolase in host metabolism: Potential for influencing gastrointestinal microbe-host crosstalk. Gut Microbes, 2014, 5, 669-674.	9.8	99
136	<i>Helicobacter pylori</i> Modulates Lymphoepithelial Cell Interactions Leading to Epithelial Cell Damage through Fas/Fas Ligand Interactions. Infection and Immunity, 2000, 68, 4303-4311.	2.2	97
137	Unconjugated Bile Acids Influence Expression of Circadian Genes: A Potential Mechanism for Microbe-Host Crosstalk. PLoS ONE, 2016, 11, e0167319.	2.5	97
138	Review article: dietary fibre in the era of microbiome science. Alimentary Pharmacology and Therapeutics, 2019, 49, 506-515.	3.7	97
139	Mechanisms of Action of Probiotics in Intestinal Diseases. Scientific World Journal, The, 2007, 7, 31-46.	2.1	96
140	IMMUNOLOGY: Therapeutic Manipulation of Gut Flora. Science, 2000, 289, 1311-1312.	12.6	95
141	Probiotics in Perspective. Gastroenterology, 2010, 139, 1808-1812.	1.3	95
142	Neutrophil cytoplasmic antibodies: A link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology, 1991, 100, 1385-1391.	1.3	95
143	Determinants of Reduced Genetic Capacity for Butyrate Synthesis by the Gut Microbiome in Crohnâ∈™s Disease and Ulcerative Colitis. Journal of Crohn's and Colitis, 2018, 12, 204-216.	1.3	93
144	Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek, 1999, 76, 279-92.	1.7	93

#	Article	IF	CITATIONS
145	The gut microbiota—a clinical perspective on lessons learned. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 609-614.	17.8	92
146	Gut microbiota and obesity: Role in aetiology and potential therapeutic target. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 585-597.	2.4	92
147	Pathogenesis of ulcerative colitis. Lancet, The, 1993, 342, 407-411.	13.7	91
148	Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Hepatology, 1999, 29, 904-907.	7.3	91
149	Altered Mechanisms of Apoptosis in Colon Cancer: Fas Resistance and Counterattack in the Tumorâ€Immune Conflict. Annals of the New York Academy of Sciences, 2000, 910, 178-195.	3.8	91
150	Impact of probiotics in women with gestational diabetes mellitus on metabolic health: a randomized controlled trial. American Journal of Obstetrics and Gynecology, 2015, 212, 496.e1-496.e11.	1.3	90
151	The evolving epidemiology of inflammatory bowel disease. Current Opinion in Gastroenterology, 2009, 25, 301-305.	2.3	89
152	Dietary <i>trans</i> -10, <i>cis</i> -12-conjugated linoleic acid alters fatty acid metabolism and microbiota composition in mice. British Journal of Nutrition, 2015, 113, 728-738.	2.3	89
153	Induction and Activation of Adaptive Immune Populations During Acute and Chronic Phases of a Murine Model of Experimental Colitis. Digestive Diseases and Sciences, 2011, 56, 79-89.	2.3	88
154	Cognitive performance in irritable bowel syndrome: evidence of a stress-related impairment in visuospatial memory. Psychological Medicine, 2014, 44, 1553-1566.	4.5	88
155	Neuroendocrine modulation of the immune system. Digestive Diseases and Sciences, 1988, 33, 41S-49S.	2.3	86
156	Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. American Journal of Physiology - Renal Physiology, 2006, 290, G839-G845.	3.4	85
157	Seasonality of vitamin D status and bone turnover in patients with Crohn's disease. Alimentary Pharmacology and Therapeutics, 2005, 21, 1073-1083.	3.7	84
158	Loss of vagal anti-inflammatory effect: in vivo visualization and adoptive transfer. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2009, 297, R1118-R1126.	1.8	84
159	Biochemical and metabolomic phenotyping in the identification of a vitamin D responsive metabotype for markers of the metabolic syndrome. Molecular Nutrition and Food Research, 2011, 55, 679-690.	3.3	84
160	Tumour necrosis factor $5\hat{a} \in 2$ promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families. Genes and Immunity, 2001, 2, 82-87.	4.1	83
161	Addressing the "Fas Counterattack―Controversy: Blocking Fas Ligand Expression Suppresses Tumor Immune Evasion of Colon Cancer∢i>In vivo∢/i>. Cancer Research, 2005, 65, 9817-9823.	0.9	83
162	Pellino3 ubiquitinates RIP2 and mediates Nod2-induced signaling and protective effects in colitis. Nature Immunology, 2013, 14, 927-936.	14.5	83

#	Article	IF	CITATIONS
163	Microbiome and metabolome modifying effects of several cardiovascular disease interventions in apo-Eâ $^{\circ}$ / \hat{a}° mice. Microbiome, 2017, 5, 30.	11.1	83
164	Is nutrition an aetiological factor for inflammatory bowel disease?. European Journal of Gastroenterology and Hepatology, 2003, 15, 607-613.	1.6	82
165	Coeliac disease and epilepsy. QJM - Monthly Journal of the Association of Physicians, 1998, 91, 303-308.	0.5	81
166	Probiotic Colonization of the Adherent Mucus Layer of HT29MTXE12 Cells Attenuates <i>Campylobacter jejuni</i> Virulence Properties. Infection and Immunity, 2010, 78, 2812-2822.	2.2	81
167	The colonic microbiota in health and disease. Current Opinion in Gastroenterology, 2013, 29, 49-54.	2.3	81
168	Immunologic Mechanisms in Intestinal Diseases. Annals of Internal Medicine, 1987, 106, 853.	3.9	80
169	Probiotics: towards demonstrating efficacy. Trends in Food Science and Technology, 1999, 10, 393-399.	15.1	80
170	Exopolysaccharide-Producing Probiotic Lactobacilli Reduce Serum Cholesterol and Modify Enteric Microbiota in ApoE-Deficient Mice. Journal of Nutrition, 2014, 144, 1956-1962.	2.9	80
171	High prevalence of celiac disease among patients with insulin-dependent (type I) diabetes mellitus. American Journal of Gastroenterology, 1997, 92, 2210-2.	0.4	80
172	Association of NOD2 with Crohn's Disease in a homogenous Irish population. European Journal of Human Genetics, 2003, 11, 237-244.	2.8	76
173	Celiac Disease and the Transition from Childhood to Adulthood: A 28-Year Follow-Up. American Journal of Gastroenterology, 2004, 99, 2437-2441.	0.4	76
174	Radiologic Imaging in Cystic Fibrosis. Chest, 2012, 141, 1575-1583.	0.8	76
175	Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology, 1991, 100, 1385-91.	1.3	76
176	Increased neutrophil receptors for and response to the proinflammatory bacterial peptide formyl-methionyl-leucyl-phenylalanine in Crohn's disease. Gastroenterology, 1989, 97, 20-28.	1.3	75
177	IBS: an epigenetic perspective. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 465-471.	17.8	75
178	Mechanism of protection of transepithelial barrier function by <i>Lactobacillus salivarius</i> : strain dependence and attenuation by bacteriocin production. American Journal of Physiology - Renal Physiology, 2012, 303, G1029-G1041.	3.4	75
179	Fas counter-attack–the best form of tumor defense?. Nature Medicine, 1999, 5, 267-268.	30.7	74
180	CORK Study in Cystic Fibrosis. Chest, 2018, 153, 395-403.	0.8	74

#	Article	IF	CITATIONS
181	Social interaction-induced activation of RNA splicing in the amygdala of microbiome-deficient mice. ELife, 2018, 7, .	6.0	73
182	Biological behaviour and clinical implications of micrometastases. British Journal of Surgery, 2002, 87, 1629-1639.	0.3	72
183	Probiotics: An Emerging Therapy. Current Pharmaceutical Design, 2005, 11, 3-10.	1.9	72
184	Vitamin K Status in Patients with Crohn's Disease and Relationship to Bone Turnover. American Journal of Gastroenterology, 2004, 99, 2178-2185.	0.4	71
185	Substance P and other neuropeptides do not induce mediator release in isolated human intestinal mast cells. Neurogastroenterology and Motility, 2004, 16, 185-193.	3.0	70
186	Physiological Basis for Novel Drug Therapies Used to Treat the Inflammatory Bowel Diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. American Journal of Physiology - Renal Physiology, 2005, 288, G417-G421.	3.4	70
187	Irritable Bowel Syndrome: Shifting the Focus Toward the Gut Microbiota. Gastroenterology, 2007, 133, 340-342.	1.3	69
188	Four men in a boat: Ultra-endurance exercise alters the gut microbiome. Journal of Science and Medicine in Sport, 2019, 22, 1059-1064.	1.3	69
189	The Gut Microbiota in Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2017, 46, 143-154.	2.2	68
190	Sulfasalazine inhibits the binding of TNFα to its receptor. Immunopharmacology, 1990, 20, 217-224.	2.0	67
191	Coeliac disease and autoimmune Addison's disease: a clinical pitfall. QJM - Monthly Journal of the Association of Physicians, 2002, 95, 79-82.	0.5	67
192	Investigation of the Genetic Influence of the OPG, VDR (Fok1), and COLIA1 Sp1 Polymorphisms on BMD in the Irish Population. Calcified Tissue International, 2002, 71, 26-35.	3.1	67
193	Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for Clostridioides difficile infection. BMC Gastroenterology, 2018, 18, 131.	2.0	67
194	Viral clearance in hepatitis C (1b) infection: Relationship with human leukocyte antigen class II in a homogeneous population. Hepatology, 2000, 31, 1334-1337.	7.3	65
195	Anemia in patients with chronic inflammatory bowel disease. American Journal of Gastroenterology, 2001, 96, 2296-2298.	0.4	63
196	Impact of Administered <i>Bifidobacterium</i> on Murine Host Fatty Acid Composition. Lipids, 2010, 45, 429-436.	1.7	63
197	Probiotics and inflammatory bowel disease: from fads and fantasy to facts and future. British Journal of Nutrition, 2002, 88, s5-s9.	2.3	62
198	Determinants of vitamin D status in adult Crohn's disease patients, with particular emphasis on supplemental vitamin D use. European Journal of Clinical Nutrition, 2006, 60, 889-896.	2.9	62

#	Article	IF	CITATIONS
199	Identification of a Unique Hybrid Macrophage-Polarization State following Recovery from Lipopolysaccharide Tolerance. Journal of Immunology, 2014, 192, 427-436.	0.8	62
200	A Bifidobacterial pilusâ€associated protein promotes colonic epithelial proliferation. Molecular Microbiology, 2019, 111, 287-301.	2.5	62
201	The Mycobacteria Story in Crohn's Disease. American Journal of Gastroenterology, 2005, 100, 1537-1538.	0.4	61
202	Protective effects of <i>Lactobacillus reuteri</i> and <i>Bifidobacterium infantis</i> in murine models for colitis do not involve the vagus nerve. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 295, R1131-R1137.	1.8	61
203	Gene silencing of TNF-alpha in a murine model of acute colitis using a modified cyclodextrin delivery system. Journal of Controlled Release, 2013, 168, 28-34.	9.9	61
204	Degradation of the extracellular matrix components by bacterial-derived metalloproteases. Inflammatory Bowel Diseases, 2011, 17, 1189-1200.	1.9	60
205	Host–Flora Interactions in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2004, 10, S16-S24.	1.9	59
206	TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNFα, from CD3+CD161+ T cells to exacerbate gut inflammation. Mucosal Immunology, 2013, 6, 886-899.	6.0	59
207	Thromboembolism-an Important Manifestation of Inflammatory Bowel Disease. American Journal of Gastroenterology, 2004, 99, 1971-1973.	0.4	58
208	Prevalence and severity of periodontal disease in patients with inflammatory bowel disease. Journal of Clinical Periodontology, 1991, 18, 690-697.	4.9	57
209	Interferon-? sensitizes colonic epithelial cell lines to physiological and therapeutic inducers of colonocyte apoptosis. Journal of Cellular Physiology, 2000, 185, 331-338.	4.1	57
210	The influence of endorphins on peritoneal and mucosal mast cell secretion. Journal of Allergy and Clinical Immunology, 1984, 74, 499-504.	2.9	56
211	Probiotics in inflamatory bowel disease. Gut, 2001, 48, 609-609.	12.1	56
212	A Commentary on the Safety of Probiotics. Gastroenterology Clinics of North America, 2012, 41, 869-876.	2.2	56
213	Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice. Clinical and Experimental Immunology, 2006, 144, 273-280.	2.6	55
214	Involvement of T helper type 17 and regulatory T cell activity in <i>Citrobacter rodentium</i> invasion and inflammatory damage. Clinical and Experimental Immunology, 2009, 157, 148-154.	2.6	55
215	Natural killer cells protect mice from DSS-induced colitis by regulating neutrophil function via the NKG2A receptor. Mucosal Immunology, 2013, 6, 1016-1026.	6.0	55
216	Micrometastases in bone marrow of patients undergoing "curative―surgery for gastrointestinal cancer. Gastroenterology, 1995, 109, 1535-1540.	1.3	54

#	Article	IF	CITATIONS
217	Evidence of an enhanced central 5HT response in irritable bowel syndrome and in the rat maternal separation model. Neurogastroenterology and Motility, 2008, 20, 680-688.	3.0	54
218	Piphillin predicts metagenomic composition and dynamics from DADA2-corrected 16S rDNA sequences. BMC Genomics, 2020, 21, 56.	2.8	54
219	TNF- $\hat{l}\pm$ synergises with IFN- \hat{l}^3 to induce caspase-8-JAK1/2-STAT1-dependent death of intestinal epithelial cells. Cell Death and Disease, 2021, 12, 864.	6.3	54
220	The Fas Counterattack: A Molecular Mechanism of Tumor Immune Privilege. Molecular Medicine, 1997, 3, 294-300.	4.4	53
221	Pregnancy and pregnancy outcome in hepatitis C type 1b. QJM - Monthly Journal of the Association of Physicians, 2000, 93, 597-601.	0.5	53
222	Natural Killer Cells Protect against Mucosal and Systemic Infection with the Enteric Pathogen Citrobacter rodentium. Infection and Immunity, 2013, 81, 460-469.	2.2	53
223	Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma?. Clinical and Experimental Immunology, 2016, 183, 358-368.	2.6	53
224	Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in inflammatory bowel disease. Clinical and Experimental Immunology, 2010, 162, 108-115.	2.6	52
225	Human mucosal cytotoxic effector cells. Gastroenterology, 1987, 92, 1951-1957.	1.3	51
226	Probiotics and inflammatory bowel disease: Is there a scientific rationale?. Inflammatory Bowel Diseases, 0, 6, 107-115.	1.9	51
227	A prospective comparison of laparoscopy and imaging in the staging of esophagogastric cancer before surgery. American Journal of Gastroenterology, 1995, 90, 2191-4.	0.4	51
228	Substance P (neurokinin-1) receptor is a marker of human mucosal but not peripheral mononuclear cells: molecular quantitation and localization. Journal of Immunology, 1998, 161, 2232-40.	0.8	51
229	Natural fluctuations of hepatitis C viral load in a homogeneous patient population: A prospective study. Hepatology, 2000, 31, 225-229.	7.3	50
230	HLA class II genes determine the natural variance of hepatitis C viral load. Hepatology, 2001, 33, 224-230.	7.3	50
231	Correlation of probioticLactobacillus salivariusgrowth phase with its cell wall-associated proteome. FEMS Microbiology Letters, 2005, 252, 153-159.	1.8	50
232	Modulation of pathogen-induced CCL20 secretion from HT-29 human intestinal epithelial cells by commensal bacteria. BMC Immunology, 2009, 10, 54.	2.2	50
233	Gut microbiota modulation and implications for host health: Dietary strategies to influence the gut–brain axis. Innovative Food Science and Emerging Technologies, 2014, 22, 239-247.	5. 6	50
234	Bifidobacterium breve Bif195 Protects Against Small-Intestinal Damage Caused by Acetylsalicylic Acid in Healthy Volunteers. Gastroenterology, 2019, 157, 637-646.e4.	1.3	50

#	Article	IF	Citations
235	Hidradenitis suppurativa. Glucose tolerance, clinical, microbiologic, and immunologic features and HLA frequencies in 27 patients. Archives of Dermatology, 1988, 124, 1043-1046.	1.4	49
236	Manipulation of the bacterial flora in inflammatory bowel disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 47-61.	2.4	48
237	Gut Microbes: From Bugs to Drugs. American Journal of Gastroenterology, 2010, 105, 275-279.	0.4	48
238	Recombinant lactobacilli expressing linoleic acid isomerase can modulate the fatty acid composition of host adipose tissue in mice. Microbiology (United Kingdom), 2011, 157, 609-615.	1.8	48
239	Microbiome and health implications for ethnic minorities after enforced lifestyle changes. Nature Medicine, 2020, 26, 1089-1095.	30.7	48
240	Fas ligand upregulation is an early event in colonic carcinogenesis. Journal of Clinical Pathology, 2001, 54, 598-604.	2.0	47
241	Targeting the Fas/Fas ligand pathway in cancer. Expert Opinion on Therapeutic Targets, 2005, 9, 1031-1044.	3.4	47
242	Moderate-intensity aerobic and resistance exercise is safe and favorably influences body composition in patients with quiescent Inflammatory Bowel Disease: a randomized controlled cross-over trial. BMC Gastroenterology, 2019, 19, 29.	2.0	47
243	Intranasal Bifidobacterium longum protects against viral-induced lung inflammation and injury in a murine model of lethal influenza infection. EBioMedicine, 2020, 60, 102981.	6.1	47
244	Human mucosal T-cell cytotoxicity. Gastroenterology, 1988, 94, 960-967.	1.3	46
245	The Inflammatory Response Within Dukes' B Colorectal Cancers: Implications for Progression of Micrometastases and Patient Survival. American Journal of Gastroenterology, 2000, 95, 3607-3614.	0.4	46
246	The effect of exercise interventions on inflammatory biomarkers in healthy, physically inactive subjects: a systematic review. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 629-637.	0.5	46
247	Expression of Fas (CD95/APO-1) Ligand by Human Breast Cancers: Significance for Tumor Immune Privilege. Vaccine Journal, 1999, 6, 457-463.	2.6	46
248	Neurokinin-1 receptor (NK-1R) expression is induced in human colonic epithelial cells by proinflammatory cytokines and mediates proliferation in response to substance P. Journal of Cellular Physiology, 2003, 197, 30-41.	4.1	45
249	Altered levels of biochemical indices of bone turnover and bone-related vitamins in patients with Crohn's disease and ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2006, 23, 1007-1016.	3.7	45
250	Diagnostic Accuracy of Computed Tomography Using Lower Doses of Radiation for Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology, 2012, 10, 886-892.	4.4	45
251	Mutagenesis by Microbe: the Role of the Microbiota in Shaping the Cancer Genome. Trends in Cancer, 2020, 6, 277-287.	7.4	45
252	Inflammatory bowel diseaseâ€"From mechanisms to treatment strategies. Autoimmunity, 2010, 43, 463-477.	2.6	44

#	Article	IF	CITATIONS
253	Microbial regulation of hippocampal miRNA expression: Implications for transcription of kynurenine pathway enzymes. Behavioural Brain Research, 2017, 334, 50-54.	2.2	44
254	Hermansky-Pudlak syndrome: an immunologic assessment of 15 cases. American Journal of Medicine, 1988, 85, 823-828.	1.5	43
255	Constitutive ERK1/2 Activation in Esophagogastric Rib Bone Marrow Micrometastatic Cells Is MEK-independent. Journal of Biological Chemistry, 2001, 276, 15537-15546.	3.4	43
256	Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-Î ² expression. British Journal of Cancer, 2003, 89, 1345-1351.	6.4	43
257	Metabolic activity of probiotics—Oxalate degradation. Veterinary Microbiology, 2009, 136, 100-107.	1.9	43
258	Mycobacterium avium subsp. Paratuberculosis (MAP) as a modifying factor in Crohn $\hat{E}\frac{1}{4}$ s disease. Inflammatory Bowel Diseases, 2010, 16, 296-304.	1.9	43
259	The influence of rosuvastatin on the gastrointestinal microbiota and host gene expression profiles. American Journal of Physiology - Renal Physiology, 2017, 312, G488-G497.	3.4	43
260	V. Mechanisms of immunologic sensation of intestinal contents. American Journal of Physiology - Renal Physiology, 2000, 278, G191-G196.	3.4	42
261	A Randomised Controlled Trial of a Probiotic Lactobacillus Strain in Healthy Adults: Assessment of its Delivery, Transit and Influence on Microbial Flora and Enteric Immunity. Microbial Ecology in Health and Disease, 2002, 14, 81-89.	3.5	42
262	A prospective feasibility study of sub-millisievert abdominopelvic CT using iterative reconstruction in Crohn's disease. European Radiology, 2013, 23, 2503-2512.	4.5	42
263	Prevalence and characterization of Clostridium perfringens from the faecal microbiota of elderly Irish subjects. Journal of Medical Microbiology, 2013, 62, 457-466.	1.8	42
264	Mast cell heterogeneity. Canadian Journal of Physiology and Pharmacology, 1984, 62, 734-737.	1.4	41
265	Differential Expression of Neurokinin-1 Receptor by Human Mucosal and Peripheral Lymphoid Cells. Vaccine Journal, 2000, 7, 371-376.	2.6	40
266	Probiotics: A Perspective on Problems and Pitfalls. Scandinavian Journal of Gastroenterology, 2003, 38, 34-36.	1.5	40
267	High levels of Lymphotoxin-Beta (LT-Beta) gene expression in rheumatoid arthritis synovium: clinical and cytokine correlations. Rheumatology International, 2008, 28, 979-986.	3.0	40
268	Therapeutic implications of manipulating and mining the microbiota. Journal of Physiology, 2009, 587, 4175-4179.	2.9	40
269	Bifidobacterium Infantis 35624 Protects Against Salmonella -Induced Reductions in Digestive Enzyme Activity in Mice by Attenuation of the Host Inflammatory Response. Clinical and Translational Gastroenterology, 2012, 3, e15.	2.5	40
270	Radiation Exposure From Diagnostic Imaging Among Patients With Gastrointestinal Disorders. Clinical Gastroenterology and Hepatology, 2012, 10, 259-265.	4.4	40

#	Article	IF	CITATIONS
271	Suggestive Linkage of 2p22-25 and 11q12-13 with Low Bone Mineral Density at the Lumbar Spine in the Irish Population. Calcified Tissue International, 2003, 72, 651-658.	3.1	39
272	Fas Ligand Promotes Tumor Immune Evasion of Colon Cancer In Vivo. Cell Cycle, 2006, 5, 246-249.	2.6	38
273	Portrait of a canine probiotic Bifidobacterium—From gut to gut. Veterinary Microbiology, 2009, 139, 106-112.	1.9	38
274	Bioavailability of the anti-clostridial bacteriocin thuricin CD in gastrointestinal tract. Microbiology (United Kingdom), 2014, 160, 439-445.	1.8	38
275	Increased soluble interleukin 2 receptor levels in schizophrenia. Schizophrenia Research, 1998, 29, 263-267.	2.0	37
276	Mucosal subepithelial binding sites for the bacterial chemotactic peptide, formyl-methionyl-leucyl-phenylalanine (FMLP). Gut, 1998, 42, 374-379.	12.1	37
277	Bifidobacterium infantis suppression of Peyer's patch MIP-1α and MIP-1β secretion during Salmonella infection correlates with increased local CD4+CD25+ T cell numbers. Cellular Immunology, 2013, 281, 134-140.	3.0	37
278	Selective influence of host microbiota on cAMPâ€mediated ion transport in mouse colon. Neurogastroenterology and Motility, 2014, 26, 887-890.	3.0	37
279	Exercise, fitness, and the gut. Current Opinion in Gastroenterology, 2016, 32, 67-73.	2.3	37
280	Intestinal mucosal mast cells: isolation from rat lamina propria and purification using unit gravity velocity sedimentation. Immunology, 1985, 55, 721-8.	4.4	37
281	Modulation of ongoing human immunoglobulin synthesis by natural killer cells. Cellular Immunology, 1987, 107, 74-88.	3.0	36
282	Persistence of hepatitis C virus in a white population: Associations with human leukocyte antigen class 1. Human Immunology, 2004, 65, 745-751.	2.4	36
283	Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders, from Rationale to Reality. Gastroenterology Clinics of North America, 2010, 39, 721-726.	2.2	36
284	The Use of a Mini-Bioreactor Fermentation System as a Reproducible, High-Throughput ex vivo Batch Model of the Distal Colon. Frontiers in Microbiology, 2018, 9, 1844.	3.5	36
285	The gut virome in Irritable Bowel Syndrome differs from that of controls. Gut Microbes, 2021, 13, 1-15.	9.8	36
286	Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity. Digestive Diseases and Sciences, 1994, 39, 1638-1641.	2.3	35
287	Type 1 diabetes mellitus, coeliac disease, and lymphoma: a report of four cases. Diabetic Medicine, 1999, 16, 614-617.	2.3	35
288	Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells. British Journal of Cancer, 2008, 99, 502-512.	6.4	35

#	Article	IF	Citations
289	Asymptomatic carriage of Clostridium difficile in an Irish continuing care institution for the elderly: prevalence and characteristics. Irish Journal of Medical Science, 2010, 179, 245-250.	1.5	35
290	A pilot study demonstrating the altered gut microbiota functionality in stable adults with Cystic Fibrosis. Scientific Reports, 2017, 7, 6685.	3.3	35
291	Altered Skin and Gut Microbiome in Hidradenitis Suppurativa. Journal of Investigative Dermatology, 2022, 142, 459-468.e15.	0.7	35
292	Neutrophil autoantibodies in inflammatory Bowel disease: Are they important?. Gastroenterology, 1994, 107, 586-589.	1.3	34
293	The microbiota in inflammatory bowel disease: friend, bystander, and sometime-villain. Nutrition Reviews, 2012, 70, S31-S37.	5.8	34
294	Tissue viral load variability in chronic hepatitis C. American Journal of Gastroenterology, 2001, 96, 3384-3389.	0.4	33
295	Bifidobacterium animalis AHC7 protects against pathogen-induced NF-κB activation in vivo. BMC Immunology, 2010, 11, 63.	2.2	33
296	Probiotics in Transition. Clinical Gastroenterology and Hepatology, 2012, 10, 1220-1224.	4.4	33
297	Translating the gut microbiome: ready for the clinic?. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 656-661.	17.8	33
298	Neuroimmunomodulation in Inflammatory Bowel Disease: How Far from "Bench―to "Bedside�a. Annals of the New York Academy of Sciences, 1998, 840, 723-734.	3.8	32
299	Role of Radiologic Imaging in Irritable Bowel Syndrome: Evidence-based Review. Radiology, 2012, 262, 485-494.	7. 3	32
300	Brain-gut axis and mucosal immunity: a perspective on mucosal psychoneuroimmunology. Seminars in Gastrointestinal Disease, 1999, 10, 8-13.	0.8	32
301	Screening for asymptomatic celiac disease among patients referred for bone densitometry measurement. Bone, 2003, 33, 970-974.	2.9	31
302	Gut microbiota: implications for sports and exercise medicine. British Journal of Sports Medicine, 2017, 51, 700-701.	6.7	31
303	The survival and colonic adhesion of Bifidobacterium infantis in patients with ulcerative colitis. International Dairy Journal, 2002, 12, 197-200.	3.0	30
304	Use of bioluminescence imaging to track neutrophil migration and its inhibition in experimental colitis. Clinical and Experimental Immunology, 2010, 162, 188-196.	2.6	30
305	Bifidobacterium breve with $\hat{l}\pm$ -Linolenic Acid and Linoleic Acid Alters Fatty Acid Metabolism in the Maternal Separation Model of Irritable Bowel Syndrome. PLoS ONE, 2012, 7, e48159.	2.5	30
306	The fecal mycobiome in patients with Irritable Bowel Syndrome. Scientific Reports, 2021, 11, 124.	3.3	30

#	Article	IF	CITATIONS
307	Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor. Journal of Cystic Fibrosis, 2021, 20, 747-753.	0.7	30
308	Comparative Aspects of Mast Cell Heterogeneity in Different Species and Sites. International Archives of Allergy and Immunology, 1985, 77, 126-129.	2.1	29
309	Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack. Ecological Management and Restoration, 1999, 12, 83-89.	0.4	29
310	Prevalence of bone marrow micrometastases in esophagogastric cancer patients with and without neoadjuvant chemoradiotherapy. Journal of Surgical Research, 2004, 117, 121-126.	1.6	29
311	Immunomodulatory effects of feeding with Bifidobacterium longum on allergen-induced lung inflammation in the mouse. Pulmonary Pharmacology and Therapeutics, 2012, 25, 325-334.	2.6	29
312	Preparation of a standardised faecal slurry for ex-vivo microbiota studies which reduces inter-individual donor bias. Journal of Microbiological Methods, 2016, 129, 109-116.	1.6	29
313	Language, numeracy and logic in microbiome science. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 387-388.	17.8	29
314	Coeliac disease and diabetes mellitus: a study of 24 patients with HLA typing. The Quarterly Journal of Medicine, 1982, 51, 329-35.	1.0	29
315	A Gut ReactionLymphoepithelial Communication in the Intestine. Science, 1997, 275, 1897-0.	12.6	28
316	Relation between colitis and colon cancer. Lancet, The, 2001, 357, 246-247.	13.7	28
317	Soluble interleukin 2 receptor levels in families of people with schizophrenia. Schizophrenia Research, 2002, 56, 235-239.	2.0	28
318	Bcl-xL expression in vivo in rheumatoid synovium. Clinical Rheumatology, 2006, 25, 789-793.	2.2	28
319	The hybrid science of diet, microbes, and metabolic health. American Journal of Clinical Nutrition, 2011, 94, 1-2.	4.7	28
320	Regional immunosuppression in esophageal squamous cancer: evidence from functional studies with matched lymph nodes. Journal of Immunology, 1996, 157, 4717-20.	0.8	28
321	Medical Treatment of Inflammatory Bowel Disease. Annual Review of Medicine, 1992, 43, 125-133.	12.2	27
322	Chapter 26 Neurotransmitters and cytokines in CNS pathology. Progress in Brain Research, 1994, 103, 319-330.	1.4	27
323	Translating the microbiota to medicine. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 72-74.	17.8	27
324	Enhanced peripheral blood T-cell cytotoxicity in inflammatory bowel disease. Journal of Clinical Immunology, 1989, 9, 55-64.	3.8	26

#	Article	IF	CITATIONS
325	Cogan's syndrome: present and future directions. Rheumatology International, 2009, 29, 1117-1121.	3.0	26
326	Fiber man meets microbial man. American Journal of Clinical Nutrition, 2015, 101, 1-2.	4.7	26
327	Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit different stages of the NK and NKCF lytic processes. Immunopharmacology, 1986, 11, 111-118.	2.0	25
328	Enhanced neutrophil chemiluminescence in familial mediterranean fever. Journal of Clinical Immunology, 1988, 8, 148-156.	3.8	25
329	Enteric neuropathophysiology and inflammatory bowel disease. Neurogastroenterology and Motility, 1998, 10, 185-187.	3.0	25
330	Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cellsin vivo. International Journal of Cancer, 2003, 107, 209-214.	5.1	25
331	Differential regulation of Tollâ€like receptor signalling in spleen and Peyer's patch dendritic cells. Immunology, 2010, 131, 438-448.	4.4	25
332	Bifidobacterium breve with \hat{l}_{\pm} -linolenic acid alters the composition, distribution and transcription factor activity associated with metabolism and absorption of fat. Scientific Reports, 2017, 7, 43300.	3.3	25
333	Clostridium difficile carriage in adult cystic fibrosis (CF); implications for patients with CF and the potential for transmission of nosocomial infection. Journal of Cystic Fibrosis, 2017, 16, 291-298.	0.7	25
334	Tumour-associated and non-tumour-associated microbiota: Addendum. Gut Microbes, 2018, 9, 1-5.	9.8	25
335	The Gut Microbiota in Causation, Detection, and Treatment of Cancer. American Journal of Gastroenterology, 2019, 114, 1036-1042.	0.4	25
336	Modelling the major histocompatibility complex susceptibility to RA using the MASC method. , 1998, 15, 419-430.		24
337	Antimicrobials. Gut Microbes, 2013, 4, 48-53.	9.8	24
338	Why is Celiac Disease So Common in Ireland?. Perspectives in Biology and Medicine, 2001, 44, 342-352.	0.5	23
339	The Sphingosine-1-Phosphate Analogue FTY720 Impairs Mucosal Immunity and Clearance of the Enteric Pathogen Citrobacter rodentium. Infection and Immunity, 2012, 80, 2712-2723.	2.2	23
340	The small bowel microbiota. Current Opinion in Gastroenterology, 2015, 31, 130-136.	2.3	23
341	Inferred Hepatitis C Virus Quasispecies Diversity Is Influenced by Choice of DNA Polymerase in Reverse Transcriptase-Polymerase Chain Reactions. Analytical Biochemistry, 2001, 289, 137-146.	2.4	22
342	Role of probiotics in the treatment of intestinal infections and inflammation. Current Opinion in Gastroenterology, 2002, 18, 40-45.	2.3	22

#	Article	IF	Citations
343	IgG-Mediated Food Intolerance in Irritable Bowel Syndrome: A Real Phenomenon or an Epiphenomenom?. American Journal of Gastroenterology, 2005, 100, 1558-1559.	0.4	22
344	Intestinal tuberculosis mimicking Crohn??s disease: lessons relearned in a new era. European Journal of Gastroenterology and Hepatology, 2007, 19, 347-349.	1.6	22
345	The colonic microflora and probiotic therapy in health and disease. Current Opinion in Gastroenterology, 2011, 27, 61-65.	2.3	22
346	The Colonic Microbiota and Colonic Disease. Current Gastroenterology Reports, 2012, 14, 446-452.	2.5	22
347	The effect of a probiotic blend on gastrointestinal symptoms in constipated patients: a double blind, randomised, placebo controlled 2-week trial. Beneficial Microbes, 2019, 10, 617-627.	2.4	22
348	Regulation of CEACAM Family Members by IBD-Associated Triggers in Intestinal Epithelial Cells, Their Correlation to Inflammation and Relevance to IBD Pathogenesis. Frontiers in Immunology, 2021, 12, 655960.	4.8	22
349	Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. Journal of Clinical & Laboratory Immunology, 1987, 24, 69-74.	0.1	22
350	Fas ligand and Fas receptor are coexpressed in normal human esophageal epithelium: a potential mechanism of apoptotic epithelial turnover. Ecological Management and Restoration, 1999, 12, 90-98.	0.4	21
351	Targeting the EP1 receptor reduces Fas ligand expression and increases the antitumor immune response in an <i>in vivo</i> model of colon cancer. International Journal of Cancer, 2013, 133, 825-834.	5.1	21
352	Depth-Dependent Differences in Community Structure of the Human Colonic Microbiota in Health. PLoS ONE, 2013, 8, e78835.	2.5	21
353	Gastric digestion of \hat{l}_{\pm} -lactalbumin in adult human subjects using capsule endoscopy and nasogastric tube sampling. British Journal of Nutrition, 2014, 112, 638-646.	2.3	21
354	Defining gastrointestinal transit time using video capsule endoscopy: a study of healthy subjects. Endoscopy International Open, 2020, 08, E396-E400.	1.8	21
355	Ulcerative colitis-linked antineutrophil cytoplasmic antibody in the cotton-top tamarin model of colitis. Gastroenterology, 1992, 102, 1493-1498.	1.3	20
356	Bone Marrow Micrometastases and Gastrointestinal Cancer Detection and Significance. American Journal of Gastroenterology, 2000, 95, 1644-1651.	0.4	20
357	Upregulation of Fas-Fas-L (CD95/CD95L)-Mediated Epithelial Apoptosis—A Putative Role in Pouchitis?. Journal of Surgical Research, 2001, 98, 27-32.	1.6	20
358	Review article: colitis-associated cancer - time for new strategies. Alimentary Pharmacology and Therapeutics, 2003, 18, 6-9.	3.7	20
359	CD38 is associated with premenopausal and postmenopausal bone mineral density and postmenopausal bone loss. Journal of Bone and Mineral Metabolism, 2005, 24, 28-35.	2.7	20
360	Steroid allergy in patients with inflammatory bowel disease. British Journal of Dermatology, 2007, 157, 967-969.	1.5	20

#	Article	IF	Citations
361	Increased Risk of Miscarriage and Ectopic Pregnancy Among Women With Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2012, 10, 902-909.	4.4	20
362	Differential intestinal Mâ€cell gene expression response to gut commensals. Immunology, 2012, 136, 312-324.	4.4	20
363	Bcl-3 deficiency protects against dextran-sodium sulphate-induced colitis in the mouse. Clinical and Experimental Immunology, 2013, 173, 332-342.	2.6	20
364	Concomitant Exposure to Ovalbumin and Endotoxin Augments Airway Inflammation but Not Airway Hyperresponsiveness in a Murine Model of Asthma. PLoS ONE, 2014, 9, e98648.	2.5	20
365	Mast Cell Heterogeneity: Effect of Anti-Allergic Compounds on Neuropeptide-Induced Histamine Release. International Archives of Allergy and Immunology, 1986, 80, 424-426.	2.1	19
366	Extending the Scope in Celiac Disease. New England Journal of Medicine, 1988, 319, 782-783.	27.0	19
367	Role of mucosal T-cell-generated cytokines in epithelial cell injury. Immunologic Research, 1991, 10, 472-478.	2.9	19
368	Antibody 'markers' in Crohn's disease: opportunity or overstatement?. Gut, 1997, 40, 557-558.	12.1	19
369	Mechanisms of adherence of a probioticLactobacillusstrain during and afterin vivoassessment in ulcerative colitis patients. Microbial Ecology in Health and Disease, 2004, 16, 96-104.	3.5	19
370	Drug Interactions in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2008, 103, 207-219.	0.4	19
371	Molecular mechanisms of probiotic action: it's all in the strains!. Gut, 2011, 60, 1026-1027.	12.1	19
372	Digestion of epithelial tight junction proteins by the commensal < i>Clostridium perfringens < /i>American Journal of Physiology - Renal Physiology, 2013, 305, G740-G748.	3.4	19
373	Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease. British Journal of Nutrition, 2014, 112, 1163-1174.	2.3	19
374	Microbial contributions to chronic inflammation and metabolic disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2016, 19, 257-262.	2.5	19
375	A randomised, double-blind, placebo-controlled clinical study: the effects of a synbiotic, Lepicol, in adults with chronic, functional constipation. International Journal of Food Sciences and Nutrition, 2017, 68, 366-377.	2.8	19
376	Quantitative analysis of mucosal oxygenation using ex vivo imaging of healthy and inflamed mammalian colon tissue. Cellular and Molecular Life Sciences, 2017, 74, 141-151.	5.4	19
377	Carbohydrate Syntrophy enhances the establishment of Bifidobacterium breve UCC2003 in the neonatal gut. Scientific Reports, 2018, 8, 10627.	3.3	19
378	Intestinal Lymphoepithelial Communication. Advances in Experimental Medicine and Biology, 1999, 473, 1-9.	1.6	19

#	Article	IF	CITATIONS
379	Activation of the p38 MAPK and ERK1/2 Pathways Is Required for Fasâ€Induced ILâ€8 Production in Colonic Epithelial Cells. Annals of the New York Academy of Sciences, 2002, 973, 161-165.	3.8	18
380	In vitro replication models for the hepatitis C virus. Journal of Viral Hepatitis, 2007, 14, 2-10.	2.0	18
381	Human BCL-G regulates secretion of inflammatory chemokines but is dispensable for induction of apoptosis by IFN- \hat{l}^3 and TNF- \hat{l}^\pm in intestinal epithelial cells. Cell Death and Disease, 2020, 11, 68.	6.3	18
382	Quantitative Measurement of mRNA Expression by Competitive RT-PCR., 1998, 92, 183-194.		17
383	Exploring the Iceberg-the Spectrum of Celiac Disease. American Journal of Gastroenterology, 2003, 98, 518-520.	0.4	17
384	Model-Based Iterative Reconstruction in CT Enterography. American Journal of Roentgenology, 2015, 205, 1173-1181.	2.2	17
385	Neutrophil autoantibodies as disease markers for ulcerative colitis. Immunologic Research, 1991, 10, 479-484.	2.9	16
386	Do Taq-generated RT-PCR products from RNA viruses accurately reflect viral genetic heterogeneity?. Journal of Viral Hepatitis, 2004, 11, 108-114.	2.0	16
387	Fas ligand expression in human and mouse cancer cell lines; a caveat on over-reliance on mRNA data. Journal of Carcinogenesis, 2006, 5, 5.	2.5	16
388	<i>Salmonella typhimurium</i> stimulation combined with tumour-derived heat shock proteins induces potent dendritic cell anti-tumour responses in a murine model. Clinical and Experimental Immunology, 2007, 149, 109-116.	2.6	16
389	Sport and recreation-related injuries and fracture occurrence among emergency department attendees: implications for exercise prescription and injury prevention. Emergency Medicine Journal, 2009, 26, 590-595.	1.0	16
390	99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: Host–microbe interactions in the gut: target for drug therapy, opportunity for drug discovery. Clinical and Experimental Immunology, 2010, 160, 92-97.	2.6	16
391	Host–microbe interactions and spatial variation of cancer in the gut. Nature Reviews Cancer, 2014, 14, 511-512.	28.4	16
392	The prophylactic use of a proton pump inhibitor before food and alcohol. Alimentary Pharmacology and Therapeutics, 2003, 17, 683-686.	3.7	15
393	Carriage of Clostridium difficile in outpatients with irritable bowel syndrome. Journal of Medical Microbiology, 2012, 61, 1290-1294.	1.8	15
394	Low-dose CT imaging of the acute abdomen using model-based iterative reconstruction: a prospective study. Emergency Radiology, 2019, 26, 169-177.	1.8	15
395	The Fas counterattack: a molecular mechanism of tumor immune privilege. Molecular Medicine, 1997, 3, 294-300.	4.4	15
396	Odd forms of inflammatory bowel disease: What can they tell us?. Gastroenterology, 1993, 104, 327-329.	1.3	14

#	Article	IF	CITATIONS
397	Current concepts of the pathogenesis of inflammatory bowel disease. Irish Journal of Medical Science, 1994, 163, 544-549.	1.5	14
398	Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor. Clinical and Experimental Metastasis, 1999, 17, 87-95.	3.3	14
399	Functional foods and probiotics: Time for gastroenterologists to embrace the concept. Current Gastroenterology Reports, 2000, 2, 345-346.	2.5	14
400	Turbo probiotics for IBD. Gastroenterology, 2001, 120, 1297-1303.	1.3	14
401	Food allergies. Current Gastroenterology Reports, 2002, 4, 373-382.	2.5	14
402	Bacterial signalling overrides cytokine signalling and modifies dendritic cell differentiation. Immunology, 2009, 128, e805-15.	4.4	14
403	Technical Advance: Function and efficacy of an α4-integrin antagonist using bioluminescence imaging to detect leukocyte trafficking in murine experimental colitis. Journal of Leukocyte Biology, 2010, 88, 1271-1278.	3.3	14
404	Minimization of Radiation Exposure due to Computed Tomography in Inflammatory Bowel Disease. ISRN Gastroenterology, 2012, 2012, 1-7.	1.5	14
405	The Future of Probiotics for Disorders of the Brain-Gut Axis. Advances in Experimental Medicine and Biology, 2014, 817, 417-432.	1.6	14
406	The effects of sustained fitness improvement on the gut microbiome: A longitudinal, repeated measures caseâ€study approach. Translational Sports Medicine, 2021, 4, 174-192.	1.1	14
407	Progress in treating esophageal adenocarcinoma. Gastroenterology, 1997, 112, 1417-1418.	1.3	13
408	Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environmental Microbiology, 2008, 10, 1382-1382.	3.8	13
409	Evaluation of colostrum-derived human mammary-associated serum amyloid A3 (M-SAA3) protein and peptide derivatives for the prevention of enteric infection: <i>in vitro</i> and in murine models of intestinal disease. FEMS Immunology and Medical Microbiology, 2009, 55, 404-413.	2.7	13
410	The role of pure iterative reconstruction in conventional dose CT enterography. Abdominal Imaging, 2015, 40, 251-257.	2.0	13
411	The Changing Phenotype of Inflammatory Bowel Disease. Gastroenterology Research and Practice, 2016, 2016, 1-9.	1.5	13
412	Mast cell heterogeneity. Monographs in Allergy, 1983, 18, 124-8.	0.2	13
413	Mucosal Substance P Receptor Expression in HIV Infection and Inflammatory Bowel Disease. NeuroImmunoModulation, 1997, 4, 70-76.	1.8	12

 $\textbf{Anti-TNF The rapy for Crohn} \hat{\mathbb{E}}1/4 \text{s Disease: A Perspective (Infliximab Is Not the Drug We Have Been Waiting) Tj ETQqQ.9 0 rgBT_{12}/Qverlock } \\ \textbf{Anti-TNF The rapy for Crohn} \hat{\mathbb{E}}1/4 \text{s Disease: A Perspective (Infliximab Is Not the Drug We Have Been Waiting) Tj ETQqQ.9 0 rgBT_{12}/Qverlock } \\ \textbf{Anti-TNF The rapy for Crohn} \hat{\mathbb{E}}1/4 \text{s Disease: A Perspective (Infliximab Is Not the Drug We Have Been Waiting)} \\ \textbf{Tj ETQqQ.9 0 rgBT}_{12}/Qverlock } \\ \textbf{Tj ETQq.9 0 rgBT}_{12}/Qverlock } \\ \textbf{Tj E$

414

#	Article	IF	Citations
415	CON: Surveillance for Ulcerative Colitis-Associated Cancer: Time to Change the Endoscopy and the Microscopy. American Journal of Gastroenterology, 2004, 99, 1633-1636.	0.4	12
416	The language of medicine: words as servants and scoundrels. Clinical Medicine, 2009, 9, 131-135.	1.9	12
417	Minimization of radiation exposure due to computed tomography in inflammatory bowel disease. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 105-110.	1.5	12
418	Darwinian Dyspepsia: An Extraordinary Scientist, an Ordinary Illness, Great Dignity. American Journal of Gastroenterology, 2012, 107, 161-164.	0.4	12
419	Separating the microbiome from the hyperbolome. Genome Medicine, 2015, 7, 17.	8.2	12
420	Encapsulated cyclosporine does not change the composition of the human microbiota when assessed ex vivo and in vivo. Journal of Medical Microbiology, 2020, 69, 854-863.	1.8	12
421	Genetic analysis of the 3' untranslated region of the tumour necrosis factor shows a highly conserved region in rheumatoid arthritis affected and unaffected subjects. Journal of Medical Genetics, 1999, 36, 214-6.	3.2	12
422	Biotinylation of a bombesin/gastrin-releasing peptide analogue for use as a receptor probe. Peptides, 1991, 12, 375-381.	2.4	11
423	Genotoxicity of Fecal Water in a Free-Living Irish Population. Nutrition and Cancer, 2002, 42, 62-69.	2.0	11
424	The prevalence of coeliac disease among female subjects having bone densitometry. Irish Journal of Medical Science, 2002, 171, 145-147.	1.5	11
425	The gut microbiota and disease – an inner repository for drug discovery. Drug Discovery Today: Therapeutic Strategies, 2007, 4, 195-200.	0.5	11
426	Impaired cognitive function in Crohn's disease: Relationship to disease activity. Brain, Behavior, & Immunity - Health, 2020, 5, 100093.	2.5	11
427	Investigating the Role of Diet and Exercise in Gut Microbe-Host Cometabolism. MSystems, 2020, 5, .	3.8	11
428	Modulation, microbiota and inflammation in the adult CF gut: A prospective study. Journal of Cystic Fibrosis, 2022, 21, 837-843.	0.7	11
429	Histological patchiness and sparing of the rectum in ulcerative colitis: refuting the dogma Journal of Clinical Pathology, 1997, 50, 354-355.	2.0	10
430	Genes, bacteria, and T cells: Ingredients for inflammatory bowel disease. Gastroenterology, 1998, 115, 1595-1596.	1.3	10
431	Immunological and genetic links in Crohn's disease. Gut, 2000, 46, 6-7.	12.1	10
432	Mycobacterium paratuberculosis Detected by Nested PCR in Intestinal Granulomas Isolated by LCM in Cases of Crohn's Disease., 2002, 193, 205-211.		10

#	Article	IF	CITATIONS
433	Nested RT-PCR: Sensitivity Controls are Essential to Determine the Biological Significance of Detected mRNA., 2002, 193, 065-079.		10
434	Viral load change and sequential evolution of entire hepatitis C virus genome in Irish recipients of single source-contaminated anti-D immunoglobulin*. Journal of Viral Hepatitis, 2005, 12, 594-603.	2.0	10
435	Plain abdominal radiographs in patients with Crohn's disease: Radiological findings and diagnostic value. Clinical Radiology, 2012, 67, 774-781.	1.1	10
436	Computed Tomography Assessment of Intestinal Gas Volumes in Functional Gastrointestinal Disorders. Journal of Neurogastroenterology and Motility, 2012, 18, 419-425.	2.4	10
437	GREB1 genetic variants are associated with bone mineral density in Caucasians. Journal of Bone and Mineral Metabolism, 2018, 36, 189-199.	2.7	10
438	Microbiome alterations in IBS. Gut, 2020, 69, 2263-2264.	12.1	10
439	A Convolutional Neural Network Deep Learning Model Trained on CD Ulcers Images Accurately Identifies NSAID Ulcers. Frontiers in Medicine, 2021, 8, 656493.	2.6	10
440	Mapping the colorectal tumor microbiota. Gut Microbes, 2021, 13, 1-10.	9.8	10
441	Critical appraisal of enteral nutrition as primary therapy in adults with Crohn's disease. American Journal of Gastroenterology, 1996, 91, 2075-9.	0.4	10
442	Successful Endoscopic Removal of a Common Bile Duct Foreign Body. Endoscopy, 1982, 14, 26-27.	1.8	9
443	Gene-targeted immunologic knockouts: New models of inflammatory bowel disease. Gastroenterology, 1994, 107, 312-314.	1.3	9
444	Type I Insulinâ€like Growth Factor Receptor Expression on Colorectal Adenocarcinoma Cell Lines Is Decreased in Response to the Chemopreventive Agent ⟨i⟩N⟨/i⟩â€Acetylâ€lâ€Cysteine. Annals of the New York Academy of Sciences, 2002, 973, 555-558.	3.8	9
445	The CD8+ Leu-7+ subset of T cells in Crohn's disease: distinction between cytotoxic and covert suppressor functions. Clinical and Experimental Immunology, 2008, 80, 387-394.	2.6	9
446	Inflammasome Signaling Regulates the Microbial–Neuroimmune Axis and Visceral Pain in Mice. International Journal of Molecular Sciences, 2021, 22, 8336.	4.1	9
447	The role of autoantibodies and autoimmunity in chronic inflammatory disorders of the gut. Current Opinion in Gastroenterology, 1992, 8, 988-992.	2.3	8
448	Infliximab Therapy for Complicated Sarcoidosis. Annals of Internal Medicine, 2002, 137, 296.	3.9	8
449	Upregulation of neurokinin-1 receptor expression in the lungs of patients with sarcoidosis. Journal of Clinical Immunology, 2003, 23, 425-435.	3.8	8
450	Oral immune tolerance to tumor specific antigens may confer growth advantage to esophageal and gastric cancers*. Ecological Management and Restoration, 2003, 16, 218-223.	0.4	8

#	Article	IF	CITATIONS
451	Probiotics and the Immune Response: How Much Can We Expect?. Journal of Pediatric Gastroenterology and Nutrition, 2004, 39, S748-S749.	1.8	8
452	Undiagnosed Maternal Celiac Disease in Pregnancy and an Increased Risk of Fetal Growth Restriction. Journal of Clinical Gastroenterology, 2009, 43, 792-793.	2.2	8
453	Shining a Light on Intestinal Traffic. Clinical and Developmental Immunology, 2012, 2012, 1-14.	3.3	8
454	CT-based estimation of intracavitary gas volumes using threshold-based segmentation: In vitro study to determine the optimal threshold range. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 289-294.	1.8	8
455	Detection of Mycobacterium avium subspecies paratuberculosis in patients with Crohn's disease is unrelated to the presence of single nucleotide polymorphisms rs2241880 (ATG16L1) and rs10045431 (IL12B). Medical Microbiology and Immunology, 2014, 203, 195-205.	4.8	8
456	32: Impact of probiotics in women with gestational diabetes mellitus on metabolic health: a randomized controlled trial. American Journal of Obstetrics and Gynecology, 2015, 212, S22.	1.3	8
457	Dietary Fiber and Gastrointestinal Disease: an Evolving Story. Current Gastroenterology Reports, 2018, 20, 59.	2.5	8
458	Host Microbiota Regulates Central Nervous System Serotonin Receptor 2C Editing in Rodents. ACS Chemical Neuroscience, 2019, 10, 3953-3960.	3.5	8
459	Efficacy of Delayed-Release Mesalamine in the Prevention of GI Symptoms Following Acute Diverticulitis: Results of the DIVA Trial. American Journal of Gastroenterology, 2010, 105, S139.	0.4	8
460	Successful combined liver and small intestine transplantation for short-gut syndrome and liver failure. Western Journal of Medicine, 1993, 158, 184-8.	0.3	8
461	IMMUNOLOGICAL TESTS TO MONITOR INFLAMMATORY BOWEL DISEASE—HAVE THEY DELIVERED YET?. American Journal of Gastroenterology, 1998, 93, 295-297.	0.4	7
462	Making microbes work for mankindâ€"clever trick or a glimpse of the future for IBD treatment?. Gastroenterology, 2004, 127, 667-668.	1.3	7
463	Esophageal intramural pseudodiverticulosis characterized by barium esophagography: a case report. Journal of Medical Case Reports, 2010, 4, 145.	0.8	7
464	Selection of Symptomatic Patients with Crohn's Disease for Abdominopelvic Computed Tomography: Role of Serum C-Reactive Protein. Canadian Association of Radiologists Journal, 2012, 63, 267-274.	2.0	7
465	Managing chronic disease in Ireland: hospital admission rates and clinical outcomes in a large ulcerative colitis population. Irish Journal of Medical Science, 2012, 181, 65-71.	1.5	7
466	Pure Iterative Reconstruction Improves Image Quality in Computed Tomography of the Abdomen and Pelvis Acquired at Substantially Reduced Radiation Doses in Patients With Active Crohn Disease. Journal of Computer Assisted Tomography, 2016, 40, 225-233.	0.9	7
467	Macronutrients, microbiome and precision nutrition. Current Opinion in Gastroenterology, 2021, 37, 145-151.	2.3	7
468	K562 killing by K, IL 2-responsive NK, and T cells involves different effector cell post-binding trigger mechanisms. Journal of Immunology, 1986, 137, 723-6.	0.8	7

#	Article	IF	Citations
469	Primary Biliary Cirrhosis associated with Coeliac Disease. Irish Medical Journal, 1983, 76, 282.	0.0	7
470	Metagenomic assembled plasmids of the human microbiome vary across disease cohorts. Scientific Reports, 2022, 12 , .	3.3	7
471	Discontent with Dysplasia Surveillance in Ulcerative Colitis. Inflammatory Bowel Diseases, 1995, 1, 80-83.	1.9	6
472	Soluble interleukin 2 receptor levels in acute and stable schizophrenia. Schizophrenia Research, 2001, 52, 143-144.	2.0	6
473	Antibiotics as a First-line Therapy for Crohnʽs Disease. Inflammatory Bowel Diseases, 2004, 10, 324-326.	1.9	6
474	An unusual phenotype in Muckle-Wells syndrome associated with NLRP3 E311K. Rheumatology, 2011, 50, 419-420.	1.9	6
475	Risk factors for hand injury in hurling: a cross-sectional study. BMJ Open, 2013, 3, e002634.	1.9	6
476	Prognostic significance of prospectively detected bone marrow micrometastases in esophagogastric cancer: 10â€year followâ€up confirms prognostic significance. Cancer Medicine, 2015, 4, 1281-1288.	2.8	6
477	Enteric Microbiota and Small Intestinal Bacterial Overgrowth. , 2010, , 1769-1778.e4.		6
478	Vip Modulates Intracellular Calcium Oscillations in Human Lymphoblasts. Immunopharmacology and Immunotoxicology, 1993, 15, 429-446.	2.4	5
479	Turning on T–Cell death and turning off Crohn's disease. Gastroenterology, 2000, 119, 1166-1168.	1.3	5
480	Medicine in the Age of " Ulysses ": James Joyce's portrait of life, medicine, and disease on a Dublin day a century ago. Perspectives in Biology and Medicine, 2006, 49, 276-285.	0.5	5
481	Are patients with IBD knowledgeable about the risks of their medications?. Inflammatory Bowel Diseases, 2008, 14, S70-S71.	1.9	5
482	The emerging role of the microbial-gastrointestinal-neural axis. Gastroenterology Insights, 2009, 1, 3.	1.2	5
483	PPO.19â€Probiotics in obese pregnancy to reduce maternal fasting glucose: A randomised controlled trial. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2014, 99, A156.1-A156.	2.8	5
484	Changing the narrative on antibiotics. Gut, 2015, 64, 1674-1675.	12.1	5
485	260 Alterations in the Microbiota in Irritable Bowel Syndrome; A Comparison of Two Geographically Distinct Cohorts. Gastroenterology, 2016, 150, S63.	1.3	5
486	Colonoscopy during an attack of severe ulcerative colitis. American Journal of Gastroenterology, 1991, 86, 1278.	0.4	5

#	Article	IF	Citations
487	Gut flora in gastrointestinal disease. The European Journal of Surgery Supplement: = Acta Chirurgica Supplement, 2002, , 47-52.	0.2	5
488	Colorectal microbiota after removal of colorectal cancer. NAR Cancer, 2022, 4, zcac011.	3.1	5
489	Cerebral intravascular coagulation complicating diabetic ketoacidosis. Irish Journal of Medical Science, 1981, 150, 156-157.	1.5	4
490	Role of the CD45 (T-200) molecule in anti-CD3-triggered T cell-mediated cytotoxicity. Cellular Immunology, 1988, 117, 99-110.	3.0	4
491	Interleukin 8, neutrophils, and acute inflammation. Gastroenterology, 1992, 103, 341-343.	1.3	4
492	Fas ligand expression by normal human esophageal squamous epithelium: Another site of immune privilege. Gastroenterology, 1998, 114, A929.	1.3	4
493	Setback for systemic therapy of esophageal cancer: Right concept, disappointing result. Gastroenterology, 1999, 117, 1020-1021.	1.3	4
494	A strategy for obtaining near full-length HCV cDNA clones (assemblicons) by assembly PCR. Journal of Virological Methods, 2005, 123, 115-124.	2.1	4
495	James Joyce and gastroenterology. Clinical Medicine, 2008, 8, 632-633.	1.9	4
496	Exercise-induced bronchoconstriction and exercise testing in an international rugby union team. Thorax, 2010, 65, 843-844.	5.6	4
497	Microbes and metabolic health. Gut, 2012, 61, 1655-1656.	12.1	4
498	A multicentre analysis of Clostridium difficile in persons with Cystic Fibrosis demonstrates that carriage may be transient and highly variable with respect to strain and level. Journal of Infection, 2021, 82, 363-370.	3.3	4
499	Anti-tnf therapy for Crohn's disease: A perspective (infliximab is not the drug we have been waiting) Tj ETQq1 1 0	.784314 r 1.9	gBT /Overlo
500	Functional characterization of mast cells generated in vitro from the mesenteric lymph node of rats infected with Nippostrongylus brasiliensis. Immunology, 1986, 57, 455-9.	4.4	4
501	Immunosuppressive and Immunomodulatory Therapy for Inflammatory Bowel Disease. Canadian Journal of Gastroenterology & Hepatology, 1993, 7, 115-120.	1.7	3
502	Intestinal graft-versus-host disease. Gastroenterology, 1998, 115, 220-222.	1.3	3
503	A significant step in the celiac puzzle. Gastroenterology, 1998, 114, 1339-1340.	1.3	3
504	Glial cells, mucosal integrity, and inflammatory bowel disease. Gastroenterology, 1999, 116, 493-494.	1.3	3

#	Article	IF	Citations
505	Colorectal cancer: still a major killer despite progress on many fronts. QJM - Monthly Journal of the Association of Physicians, 2000, 93, 131-134.	0.5	3
506	Gene therapy for food allergy. Gastroenterology, 2000, 119, 269-270.	1.3	3
507	Mutant Salmonella as vectors for gene therapy. Gastroenterology, 2001, 121, 224-226.	1.3	3
508	p53 at the crossroads of colitis and cancer. Gastroenterology, 2001, 120, 1877-1878.	1.3	3
509	Strategy for the maximization of clinically relevant information from hepatitis C virus, RT-PCR quantification. Journal of Clinical Virology, 2001, 20, 163-171.	3.1	3
510	Bacterial DNA within granulomas of patients with Crohn's disease-detection by laser capture microdissection and PCR. Gastroenterology, 2003, 124, A500.	1.3	3
511	Acromegaly and Colorectal Cancer: A Comprehensive Review of Epidemiology, Biological Mechanisms, and Clinical Implications. Hormone and Metabolic Research, 2004, 36, 70-71.	1.5	3
512	The Neglected Spectrum of Diverticular-related Disorders. Clinical Gastroenterology and Hepatology, 2013, 11, 1620-1621.	4.4	3
513	Editorial: probiotics in inflammatory bowel diseaseâ€"wrong organisms, wrong disease, or flawed concepts?. Alimentary Pharmacology and Therapeutics, 2017, 46, 632-633.	3.7	3
514	Letter: dietary fibre benefits for the oesophagusâ€"physical rather than metabolic action? Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 1368-1369.	3.7	3
515	Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. Journal of Pathology, 1998, 186, 240-246.	4.5	3
516	Immunology of Inflammatory Bowel Disease. , 1989, , 291-310.		3
517	Sonolucent Biliary Cast Preventing Endoscopic Sphincterotomy. Endoscopy, 1981, 13, 220-220.	1.8	2
518	Endoscopic sphincterotomy. Irish Journal of Medical Science, 1983, 152, 373-376.	1.5	2
519	Non-linkage of a T-Cell Receptor γ Chain Microsatellite (D7S485) to Rheumatoid Arthritis in Multiplex Families. Journal of Autoimmunity, 1995, 8, 131-138.	6.5	2
520	Appropriateness of laboratory tests: Requests for atypical pneumonia serology in a teaching hospital. Irish Journal of Medical Science, 1996, 165, 93-94.	1.5	2
521	Designer drugs for inflammatory bowel disease. Gastroenterology, 1997, 112, 2153-2154.	1.3	2
522	Escape from the Smad world by colon cancer. Gastroenterology, 1999, 116, 1496-1497.	1.3	2

#	Article	IF	Citations
523	Boneâ€marrow micrometastases in patients with brain metastases from epithelial cell tumours. QJM - Monthly Journal of the Association of Physicians, 2000, 93, 611-615.	0.5	2
524	Esophagogastric cancer-time to change the paradigm. American Journal of Gastroenterology, 2000, 95, 2153-2154.	0.4	2
525	How do intestinal T cells sense the dietary and microbial environment?. Gastroenterology, 2000, 118, 444-446.	1.3	2
526	CMV co-Infectionâ€" Does it Matter?., 0,, 159-163.		2
527	What is Indeterminate Colitis?. , 0, , 179-181.		2
528	Perplexing plain abdominal x-ray. Gut, 2011, 60, 218-218.	12.1	2
529	Increased health burden associated with <i>Clostridium difficile</i> diarrhoea in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2011, 34, 394-395.	3.7	2
530	The utilisation and diagnostic yield of radiological imaging in a specialist functional GI disorder clinic: an 11-year retrospective study. European Radiology, 2014, 24, 3097-3104.	4.5	2
531	Editorial: probiotics and <scp>IBS</scp> – where are we now?. Alimentary Pharmacology and Therapeutics, 2014, 40, 318-318.	3.7	2
532	Author response: linking lifestyle and microbes. Gut, 2015, 64, 520.1-520.	12.1	2
533	How the Irish savoured gastroenterology. Current Opinion in Gastroenterology, 2015, 31, 89-91.	2.3	2
534	The metabolic role of the microbiota. Clinical Liver Disease, 2015, 5, 91-93.	2.1	2
535	Translating Microbiome Science to Society—What's Next?. , 2016, , 465-470.		2
536	The gastrointestinal system and psychological factors. Current Opinion in Psychiatry, 1999, 12, 739-742.	6.3	2
537	The Fas-FasL system and colorectal tumours. Journal of Clinical Pathology, 2002, 55, 559-559.	2.0	2
538	When to suspect contamination rather than colonization $\hat{a} \in \text{``lessons from a putative fetal sheep microbiome. Gut Microbes, 2022, 14, 2005751.}$	9.8	2
539	Steroids in Crohn's: are They Obsolete?. , 0, , 28-31.		1
540	The pancreas, primary biliary cirrhosis and the dry gland syndrome. Irish Journal of Medical Science, 1985, 154, 387-389.	1.5	1

#	Article	IF	CITATIONS
541	Innate resistance to <i>Listeria monocytogenes</i> in tumor-bearing mice. Journal of Leukocyte Biology, 1997, 62, 726-732.	3.3	1
542	Immuno-epithelial interactions: Cytokine modulation of normal rabbit colonocyte function. In Vitro Cellular and Developmental Biology - Animal, 1998, 34, 743-746.	1.5	1
543	Cytokine induced expression of substance P (NK-1) receptors in human colonic epithelial cells. Gastroenterology, 1998, 114, A373.	1.3	1
544	Thrombosis, factor V Leiden, and inflammatory bowel disease. Gastroenterology, 1999, 116, 778-779.	1.3	1
545	Response to Dr. Gonzalez Cueto. American Journal of Gastroenterology, 2001, 96, 2794-2795.	0.4	1
546	RT-PCR for the Assessment of Genetically Heterogenous Populations of the Hepatitis C Virus. , 2002, 193, 171-188.		1
547	Synbiotics and colon cancer. , 2004, , 524-580.		1
548	Clinical Examination of the Gastrointestinal System in the 21st Century-Is the Emphasis Right?. American Journal of Gastroenterology, 2004, 99, 1874-1875.	0.4	1
549	Probiotics in Inflammatory Bowel Disease. Seminars in Colon and Rectal Surgery, 2006, 17, 55-60.	0.3	1
550	Making the Most of Methotrexate., 0,, 51-54.		1
551	Prevention and Treatment of Osteoporosis. , 0, , 201-204.		1
552	Intestinal Infections: Mimics and Precipitants of Relapse., 0,, 217-221.		1
553	Sclerosing Cholangitis— What to Do?. , 0, , 205-208.		1
554	6-Mercaptopurine Or Azathioprine?., 0,, 45-47.		1
555	Pathophysiologic Approach to Treatment of Diarrhea in Crohn's Disease. , 0, , 168-170.		1
556	Is Monitoring Necessary?., 0,, 21-24.		1
557	Do They Have a Role in Crohn's Disease?. , 0, , 25-27.		1
558	Trials and Tribulations— Interpreting Clinical Trials in IBD. , 0, , 81-84.		1

#	Article	IF	Citations
559	Pregnancy: What Drugs Can we Use?., 0,, 146-149.		1
560	Capsule Endoscopy: Do We Need It?., 0,, 1-4.		1
561	How to Prevent Growth Failure in Children. , 0, , 150-152.		1
562	Pouches for Indeterminate Colitis?., 0,, 182-184.		1
563	Probiotics, prebiotics, and inflammatory bowel disease. , 2007, , 90-116.		1
564	Mucosal Cytokine Imbalance in Irritable Bowel Syndrome (IBS). American Journal of Gastroenterology, 2007, 102, S514-S515.	0.4	1
565	Colitis-associated cancer and dysplasia surveillance: An opposing perspective. Current Gastroenterology Reports, 2007, 9, 175-176.	2.5	1
566	Bad language in gastroenterology. Current Gastroenterology Reports, 2008, 10, 91-93.	2.5	1
567	From bugs to drugsâ€"Mining the gut microbiota. Current Gastroenterology Reports, 2008, 10, 515-516.	2.5	1
568	43 The Role of T Cells in Vagal Protection Against Intestinal Inflammation. Gastroenterology, 2008, 134, A-6.	1.3	1
569	The effect of short-term phylloquinone supplementation on indices of vitamin K status and bone turnover in adult patients with Crohn's disease. Proceedings of the Nutrition Society, 2009, 68, .	1.0	1
570	The effects of probiotic supplementation on gut microbiota composition, immunological and biochemical markers in healthy volunteers. Proceedings of the Nutrition Society, 2010, 69, .	1.0	1
571	Irritable Bowel Syndrome Rates Following Organic Disease of Upper and Lower Gastrointestinal Tract. American Journal of Gastroenterology, 2010, 105, S484-S485.	0.4	1
572	MiR-146a Negatively Regulates IL-17A Inflammatory Response and is Elevated in Intestinal Epithelial Cells From Inflammatory Bowel Disease (IBD) Patients. Gastroenterology, 2011, 140, S-84.	1.3	1
573	In Search of Lost Opportunities: Marcel Proyce and James Joust Discuss Doctors, Diseases, Life and Death (a Hypothetical Conversation between Marcel Proust and James Joyce). Perspectives in Biology and Medicine, 2012, 55, 155-161.	0.5	1
574	Influence of gut microbiota and manipulation by probiotics and prebiotics on host tissue fat: Potential clinical implications. Lipid Technology, 2012, 24, 227-229.	0.3	1
575	In praise of the literary eponym–Henry V sign. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 93-94.	0.5	1
576	The impact of probiotics in obese pregnancy to reduce maternal fasting glucose: A randomized controlled trial. Proceedings of the Nutrition Society, 2014, 73, .	1.0	1

#	Article	IF	CITATIONS
577	Laparoscopy and Laparotomy. , 2016, , 698-701.		1
578	Tumors of the Biliary Tract., 2016,, 368-373.		1
579	Miscellaneous Diseases of the Stomach. , 2016, , 153-156.		1
580	Zollinger-Ellison Syndrome. , 2016, , 135-139.		1
581	Ulcerative Colitis: Clinical Manifestations and Management. , 2016, , 216-224.		1
582	Faecal microbiota transplantation (FMT): classical bedside-to-bench clinical research. QJM - Monthly Journal of the Association of Physicians, 2019, , .	0.5	1
583	Infographic. Athlete health and performance: no guts no glory. British Journal of Sports Medicine, 2020, 54, 250-250.	6.7	1
584	Transplanting Microbes for Irritable Bowels or Irritated Microbes or Both?. Gastroenterology, 2021, 160, 15-17.	1.3	1
585	Changing phenotype of inflammatory bowel disease and neglected metabolic health. Cogent Medicine, 2021, 8, .	0.7	1
586	The effect of immunosuppression on patch testing: A crossâ€sectional study in patients with inflammatory bowel disease. Contact Dermatitis, 2021, 85, 86-88.	1.4	1
587	Interferon- \hat{l}^3 sensitizes colonic epithelial cell lines to physiological and therapeutic inducers of colonocyte apoptosis. , 2000, 185, 331.		1
588	Contraindications— Absolute Or Relative?. , 0, , 59-62.		1
589	Cystic Diseases of the Liver and Biliary Tract. , 0, , 361-367.		1
590	Acute Viral Hepatitis., 0,, 374-386.		1
591	Gastrointestinal Dilation and Stent Placement. , 0, , 643-663.		1
592	Liver: Anatomy, Microscopic Structure, and Cell Types., 0,, 50-57.		1
593	Linking lifestyle with microbiota and risk of chronic inflammatory disorders. , 2009, , 93-102.		1
594	Don't forget increased risk of fetal growth restriction. BMJ: British Medical Journal, 2009, 338, b1069-b1069.	2.3	1

#	Article	IF	CITATIONS
595	Making computed tomography safer for patients with Crohn's disease. Scandinavian Journal of Gastroenterology, 2022, 57, 175-182.	1.5	1
596	Role of Natural Effector Cells in Human Gastrointestinal Disease. , 1989, , 455-479.		1
597	Discontent with dysplasia surveillance in ulcerative colitis. Inflammatory Bowel Diseases, 1995, 1, 80-3.	1.9	1
598	Treatment of Oral Crohn's Disease. , 0, , 164-167.		0
599	Hereditary angioedemaâ€"A cause of abdominal pain, often missed?. Irish Journal of Medical Science, 1981, 150, 335-337.	1.5	0
600	Biotinylated Neuropeptide Analogs: Design and Use as Probes for Target Cells in Heterogeneous Populations. Methods in Neurosciences, 1993, , 76-90.	0.5	0
601	Immunosppressive Agents in Inflammatory Bowel Disease: Current Status and Future Prospects. Canadian Journal of Gastroenterology & Hepatology, 1994, 8, 383-387.	1.7	0
602	From basic advances to the rapeutic strategies in ulcerative colitis. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.5	0
603	Irish society for rheumatology Proceedings of Annual General Meeting held 14th October, 1994 at St. James's Hospital, Dublin 8. Irish Journal of Medical Science, 1995, 164, 89-99.	1.5	0
604	Irish society of gastroenterology. Irish Journal of Medical Science, 1998, 167, 2-22.	1.5	0
605	National scientific medical meeting 1997 abstracts. Irish Journal of Medical Science, 1998, 167, 1-44.	1.5	0
606	Waterford surgical October club and surgical section, Royal Academy of Medicine Joint Surgical Symposium. Irish Journal of Medical Science, 1998, 167, 64-67.	1.5	0
607	Irish society of gastroenterology. Irish Journal of Medical Science, 1998, 167, 2-23.	1.5	0
608	Enteropathogenic E. coli: Intimacy redefined. Gastroenterology, 1998, 115, 233-234.	1.3	0
609	Alteration in the Ratio of cMyc to Mutant p53 is a Phenotypic Trait of Epithelial Cells Committed to Die by Apoptosis. Biochemical Society Transactions, 2000, 28, A29-A29.	3.4	0
610	Viral discrimination and subversion of host defense at the epithelial gateway. Gastroenterology, 2002, 123, 947-948.	1.3	0
611	A search for Mycobacterium paratuberculosis by PCR in Crohn's granulomas isolated by laser capture microdissection. Irish Journal of Medical Science, 2002, 171, 43-43.	1.5	0
612	Effective therapy for advanced gastrointestinal stromal tumors. Gastroenterology, 2003, 124, 1151-1153.	1.3	0

#	Article	IF	CITATIONS
613	The therapeutic use of probiotics in gastrointestinal inflammation. , 2003, , 169-184.		O
614	Role of antibiotics and probiotics in the management of inflammatory bowel disease., 2003, , 573-585.		0
615	Psychological Stress: Something to Worry About?. , 0, , 129-132.		0
616	Abnormal Liver Testsâ€" What Should we do About Them?., 0,, 18-20.		0
617	Pathology Reportsâ€" Pitfalls For the Unwary. , 0, , 5-7.		O
618	Use in Ulcerative Colitis., 0,, 70-73.		0
619	Pulmonary Manifestations: Rare But Real. , 0, , 213-216.		0
620	NSAIDs and COX-2 Selective Agents: Cause Or Cure of Pain in IBD?., 0, , 136-138.		0
621	Dealing With Infusion Reactions. , 0, , 67-69.		O
622	Complementary and Alternative Therapy -the Way Forward Or a Step Back?., 0, , 121-124.		0
623	Surveillance Colonoscopy in Uc: Alternatives and Ways to Improve Outcome. , 0, , 15-17.		0
624	Refractory Proctitis., 0,, 156-158.		0
625	Biologic Treatments in IBD. , 0, , 111-115.		0
626	Appendectomy For Ulcerative Colitis— A Therapeutic Option?. , 0, , 108-110.		0
627	TPMT Testing: is it Essential?., 0,, 40-44.		O
628	Databasesâ€" Are They Worth the Bother?. , 0, , 237-239.		0
629	Drugs to Avoid. , 0, , 133-135.		0
630	Iron Replacement— is it Safe and Effective?. , 0, , 139-141.		0

#	Article	IF	CITATIONS
631	Microscopic Colitis., 0,, 222-225.		0
632	Stem Cell Transplantation For IBD. , 0, , 116-120.		0
633	What is the Best Way to Image Perianal Crohn's Disease?. , 0, , 11-14.		O
634	Leukocytapheresis: Filtering Out the Facts., 0,, 105-107.		0
635	Short Bowel. , 0, , 171-174.		O
636	Nutritional Therapy For Crohn's Disease: is it For Adults?., 0,, 77-80.		0
637	Thromboembolic Disease: An Under-Recognized Complication?. , 0, , 209-212.		0
638	Cyclosporine: Balancing Risk and Benefit. , 0, , 55-58.		0
639	Probiotics— Separating Science From Snakeoil. , 0, , 89-92.		O
640	Smoking and Nicotine— Poison For Crohn's, Potion For Colitis?. , 0, , 96-99.		0
641	What to do with Dysplasia, DALMs, and Adenomas. , 0, , 189-192.		O
642	Functional Problems., 0,, 125-128.		0
643	Colitis-Associated Cancer: What's the Risk to Your Patients?. , 0, , 185-188.		O
644	Shared Care: Tactical Team Selection. , 0, , 233-236.		0
645	Genetics— Clinical and Therapeutic Applications. , 0, , 85-88.		0
646	Thiopurines: How Long Should we Use Them For?., 0,, 48-50.		0
647	Predicting Outcome in Severe UC., 0,, 153-155.		O
648	Outpatient Services— Do Doctors Still Have a Role?. , 0, , 229-232.		0

#	Article	IF	Citations
649	Mycobacterium Aviumparatuberculosis in Crohn's Disease: Player Or Spectator?., 0,, 36-39.		O
650	Infliximab and Surgery: Health Or Hazard?., 0,, 74-76.		0
651	Non-Invasive Diagnosis and Assessment. , 0, , 8-10.		0
652	Arthritides— Helping the Joints Without Harming the Gut. , 0, , 197-200.		0
653	Hepatitis B and C Viruses— How do They Affect Management of IBD?. , 0, , 142-145.		0
654	How Can we Prevent Tuberculosis?., 0,, 63-66.		0
655	Worms., 0,, 93-95.		0
656	Antibiotics: Which, When, and For How Long?., 0,, 32-35.		0
657	Management of Internal Fistulae. , 0, , 175-178.		0
658	Diverticular Colitis., 0,, 226-228.		0
659	Response to Dr. Kuenstner: More About MAP. American Journal of Gastroenterology, 2006, 101, 1158-1158.	0.4	0
660	Exploring the link between gut microbes and obesity. Future Microbiology, 2007, 2, 261-263.	2.0	0
661	Functional Foods and Gastrointestinal Disorders. , 0, , 153-174.		0
662	Preface. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 753-754.	2.4	0
663	Dietary intakes and body composition in adult patients with long-standing Crohn's disease currently in remission. Proceedings of the Nutrition Society, 2008, 67, .	1.0	0
664	Gastrointestinal Manifestations of Immunological Disorders., 0,, 2612-2631.		0
665	Improved fracture prediction when the FRAXÂ $^{\odot}$ tool is used in combination with vertebral morphometry. Bone, 2009, 44, S390-S391.	2.9	0
666	Investigating physiological variation in healthy Irish adults using a combination of traditional techniques and emerging metabolomic technologies. Proceedings of the Nutrition Society, 2010, 69, .	1.0	0

#	Article	IF	CITATIONS
667	Response to Andrews et al American Journal of Gastroenterology, 2010, 105, 2703-2704.	0.4	O
668	The Immunomodulatory Drug FTY720 Prevents Clearance of Citrobacter rodentium Infection in Mice. Gastroenterology, 2011, 140, S-325.	1.3	0
669	Stimulation of T-Cells in Irritable Bowel Syndrome (IBS) Mucosal Biopsy Tissue Releases Cytokines Which Selectively Activate Submucosal Neurons. Gastroenterology, 2011, 140, S-129.	1.3	0
670	The effect of vitamin K1 supplementation for 12 months on bone mineral density and indices of vitamin K status and bone turnover in adult Crohn's disease patients. Proceedings of the Nutrition Society, 2011, 70, .	1.0	0
671	Who needs doctors? Staying fresh in changing times. Clinical Medicine, 2011, 11, 587-588.	1.9	0
672	Response to Sprakes et al American Journal of Gastroenterology, 2011, 106, 166-167.	0.4	0
673	Shanahan's Response to Hayman Regarding Darwinian Dyspepsia. American Journal of Gastroenterology, 2012, 107, 1588.	0.4	0
674	Effects of the Intestinal Microbiota on Behavior and Brain Biochemistry. World Review of Nutrition and Dietetics, 2013, , 56-63.	0.3	0
675	CROHN'S DISEASE: HAS THE PHENOTYPE CHANGED?. Gut, 2013, 62, A22.1-A22.	12.1	0
676	THU0014â€Association between a polymorphism in the fractalkine receptor, CX3CR1, and rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 71, 158.2-158.	0.9	0
677	The sustained trajectory of small bowel research. Current Opinion in Gastroenterology, 2014, 30, 117-119.	2.3	0
678	P.1.c.004 The microbiota–gut–brain axis regulates adult hippocampal neurogenesis. European Neuropsychopharmacology, 2014, 24, S183.	0.7	0
679	Ethereal and material gain: unanticipated opportunity with illness or disability. Clinical Medicine, 2014, 14, 44-46.	1.9	0
680	DOP017 Dysbiosis in ulcerative colitis: adding the spatial component. Journal of Crohn's and Colitis, 2014, 8, S22.	1.3	0
681	Colon: anatomy and structural anomalies. , 2016, , 24-29.		0
682	Capsule and Small Bowel Endoscopy. , 2016, , 621-625.		0
683	Tumors of the Stomach. , 2016, , 149-152.		0
684	Oral Manifestation of Gastrointestinal Diseases. , 2016, , 574-581.		О

#	Article	IF	Citations
685	Short bowel syndrome., 2016,, 189-201.		O
686	Cystic Lesions of the Pancreas. , 2016, , 324-328.		0
687	Chronic Hepatitis B Viral Infection. , 2016, , 387-391.		0
688	Gastritis and Gastropathy. , 2016, , 140-148.		0
689	Hepatitis C Virus Infection. , 2016, , 392-396.		0
690	Management of Upper Gastrointestinal Hemorrhage Related to Portal Hypertension., 2016,, 664-674.		0
691	Su1939 Neuro-Immune Changes in IBS: A Link Between Microbiota, TLRs and Sensory-Related Markers?. Gastroenterology, 2016, 150, S594.	1.3	0
692	In the performing art of medicine: the doctor as actor. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 159-160.	0.5	0
693	Mechansims Underpinning Successful Faecal Microbiota Transplantation (FMT) for Recurrent Clostridium Difficile Infection. Gastroenterology, 2017, 152, S47-S48.	1.3	0
694	Visualising Bacterial Colonization Dynamics Inside the Gut Using Upconverting Nanoparticles Luminescence Imaging. , 2018, , .		0
695	Friendship in medicine: the Corrigan Club considers its demise. QJM - Monthly Journal of the Association of Physicians, 2019, , .	0.5	0
696	How to swim with sharks: a perspective on Voltaire Cousteau's primer. QJM - Monthly Journal of the Association of Physicians, 2019, 112, 61-62.	0.5	0
697	The undesirable resilience of the pejorative term "castrate-resistant prostate cancer― Irish Journal of Medical Science, 2021, , 1.	1.5	0
698	244 MICROBIOME ANALYSIS OF UPPER DIGESTIVE TRACT BIOPSY SAMPLES FROM INDIVIDUALS ALONG THE METAPLASIA-DYSPLASIA-ADENOCARCINOMA SEQUENCE Ecological Management and Restoration, 2021, 34, .	0.4	0
699	Diagnosis and Implications of Bone Marrow Micrometastases. , 2001, , 307-315.		0
700	Role of antibiotics and probiotics in the management of inflammatory bowel disease., 2003,, 573-585.		0
701	Probiotics in inflammatory bowel disease. , 2004, , 708-725.		0
702	Prevalence of 5-ASA Use in Diverticulitis and Diverticulosis by Age and Gender. American Journal of Gastroenterology, 2007, 102, S251.	0.4	0

#	Article	IF	CITATIONS
703	A Case of Herpes and Candidal Esophagitis: The Diagnostic Importance of Endoscopy in Odynophagia and Fever. American Journal of Gastroenterology, 2009, 104, S200-S201.	0.4	O
704	Oral Administration of the Probiotic Bifidobacterium Infantis 35624 to Humans Induces Immunoregulatory Responses In Vivo. American Journal of Gastroenterology, 2011, 106, S463-S464.	0.4	0
705	Complementary Human mDC and pDC Mechanisms Ensure Induction of Foxp3+ T Cells in Response to the Commensal Microbiota. American Journal of Gastroenterology, 2011, 106, S478.	0.4	0
706	Crohn's Disease: Minimizing Radiation Dose. , 2013, , 671-676.		0
707	Food Allergy and Adverse Reactions. , 1986, , 317-333.		0
708	Cytotoxic Lymphocytes in Human Intestinal Mucosa. Advances in Experimental Medicine and Biology, 1987, 216A, 457-463.	1.6	0
709	Immunosuppressive agents in IBD: current status and future prospects. , 1994, , 367-373.		0
710	The Brain-Gut Axis and the Mucosal Immunoinflammatory Response. , 1995, , 103-108.		0
711	Tumors of the Small Intestine. , 0, , 202-207.		0
712	Computed Tomography of the Gastrointestinal Tract., 0,, 756-767.		0
713	Complications of AIDS and Other Immunodeficiency States. , 0, , 501-508.		0
714	Helminthic Infections of the Gastrointestinal Tract and Liver. , 0, , 524-543.		0
715	Endoscopic Retrograde Cholangiopancreatography: Diagnostic and Therapeutic., 0,, 634-642.		0
716	Approach to the Patient with Ascites and Its Complications. , 0, , 447-458.		0
717	Obesity: Treatment and Complications. , 0, , 491-494.		0
718	Esophageal Neoplasms. , 0, , 93-101.		0
719	Gastrointestinal Manifestations of Systemic Diseases. , 0, , 544-553.		0
720	Radiation Injury in the Gastrointestinal Tract., 0,, 597-602.		0

#	Article	IF	CITATIONS
721	Endoscopic Mucosal Biopsy: Histopathological Interpretation. , 0, , 878-930.		O
722	Dysmotility of the Small Intestine and Colon. , 0, , 149-169.		0
723	Miscellaneous diseases of the small intestine. , 0, , 208-215.		O
724	Diseases of the Peritoneum, Retroperitoneum, Mesentery, and Omentum., 0,, 484-490.		O
725	Positron Emission Tomography in the Gastrointestinal Tract. , 0, , 782-803.		O
726	Endoscopic Diagnosis and Treatment of Nonvariceal Upper Gastrointestinal hemorrhage., 0,, 675-679.		0
727	Primary Sclerosing Cholangitis and Other Cholangiopathies. , 0, , 354-360.		O
728	Abdominal Angiography. , 0, , 820-841.		O
729	P493 The synthetic glycan KB295 optimises microbiome composition and function in ulcerative colitis: Results from a proof of principle human study. Journal of Crohn's and Colitis, 2022, 16, i458-i458.	1.3	O
730	From basic advances to therapeutic strategies in ulcerative colitis. QJM - Monthly Journal of the Association of Physicians, 1995, 88, 599-602.	0.5	O
731	Gastrointestinal Manifestations of Immunological Disorders. , 0, , 787-792.		O